Document:

Form of Executive Severance Benefit Plan

 EXHIBIT 10.7 

ALDER BIOPHARMACEUTICALS, INC. 

EXECUTIVE SEVERANCE BENEFIT PLAN 

1. INTRODUCTION. This Alder BioPharmaceuticals, Inc. Executive Severance Benefit Plan (the
“Plan”) amends and restates the Alder BioPharmaceuticals, Inc. Executive Change in Control Severance Benefit Plan established effective June 13, 2012. The Plan was adopted by the Board on March 13, 2014 and will
become effective without further action on the IPO Date (as defined below) (the “Effective Date”). The purpose of the Plan is to provide for the payment of severance benefits to certain eligible executive employees of Alder
BioPharmaceuticals, Inc. (the “Company”) in the event that such persons become subject to involuntary or constructive employment terminations. This Plan document also is the Summary Plan Description for the Plan. 

2. DEFINITIONS. For purposes of the Plan, the following terms are defined as follows: 

(a) “Accrued Amounts” means any unpaid annual base salary accrued through the date of a Participant’s
Qualifying Termination and any accrued but unpaid vacation pay. 
 (b) “Annual Bonus” means the annual cash
bonus that a Participant is eligible to earn, if any, under the Company’s annual cash incentive program, as in effect from time to time. 

(c) “Annual Target Bonus” means the annual bonus that a Participant is expected to earn under the
Company’s annual cash incentive program assuming achievement of target-level performance on all metrics. 
 (d)
“Board” means the Board of Directors of the Company. 
 (e) “Cause” shall
include, but not be limited to: (i) employee’s continued failure, in the reasonable opinion of the Board, to perform one or more assigned duties or responsibilities to the Company, such failure being evidenced by a written report
submitted on behalf of the Company to the Board so indicating failure and including a remedy or remedies reasonably satisfactory to the Board for correcting the asserted failure(s); (ii) failure to follow the lawful directives of
employee’s manager(s), such failure being evidenced by a written report submitted by such manager(s) to the Board so indicating failure and including a remedy or remedies reasonably satisfactory to the Board; (iii) material violation of
any Company policy; (iv) commission of any act of fraud, embezzlement, dishonesty or any other misconduct that has caused or is reasonably expected to result in material injury to the Company; (v) unauthorized use or disclosure of any
proprietary information or trade secrets of the Company or any other party to whom employee owes an obligation of nondisclosure as a result of the relationship with the Company; (vi) material breach by employee of any obligations under any
written agreement or covenant with the Company; or (vii) conviction of, or plea of “guilty” or “no contest” to, a felony under the laws of the United States or any state. 

(f) “Change in Control” shall have the meaning set forth in the Company’s 2014 Equity Incentive Plan. The
definition of Change in Control is intended to conform to the definitions of “change in ownership of a corporation” and “change in ownership of a substantial portion of a corporation’s assets” provided in Treasury Regulation
Sections 1.409A-3(i)(5)(v) and (vii). 
 (g) “Change in Control Termination” means a Participant’s
Separation from Service due to (i) dismissal or discharge by the Company for a reason other than death, disability, or Cause, or (ii) a Resignation for Good Reason, either of which occurs in connection with or within twelve

 
(12) months following the effective date of a Change in Control. In no event will a Participant’s Separation from Service due to death, disability or Cause, or a resignation by a Participant
without Good Reason, constitute a Change in Control Termination. 
 (h) “Code” means the Internal Revenue
Code of 1986, as amended. 
 (i) “Common Stock” means the common stock of the Company. 

(j) “Company” means Alder BioPharmaceuticals, Inc. or, following a Change in Control, the surviving entity
resulting from such event. 
 (k) “ERISA” means the Employee Retirement Income Security Act of 1974, as
amended. 
 (l) “IPO Date” means the date of the underwriting agreement between the Company and the
underwriter(s) managing the initial public offering of the Common Stock, pursuant to which the Common Stock is priced for the initial public offering. 

(m) “Monthly Annual Target Bonus” means a Participant’s Annual Target Bonus, divided by 12. 

(n) “Monthly Base Salary” means the Participant’s annual base salary, ignoring any decrease in annual base
salary that forms the basis for a Resignation for Good Reason, as in effect on the date of the Qualifying Termination, divided by 12. 

(o) “Non-Change in Control Termination” means a Participant’s dismissal or discharge by the Company
resulting in a Separation from Service, for a reason other than death, disability, or Cause, other than in connection with or within twelve (12) months following the effective date of a Change in Control. In no event will a Participant’s
Separation from Service due to death, disability or Cause, or a resignation by a Participant for any reason, constitute a Non-Change in Control Termination. 

(p) “Participant” means each individual who (i) is employed by the Company as an executive officer or key
employee designated by the Board, and (ii) has received and returned a signed Participation Notice. 
 (q)
“Participation Notice” means the latest notice delivered by the Company to a Participant informing the Participant that he or she is eligible to participate in the Plan, in substantially the form of
EXHIBIT A to the Plan. 
 (r) “Plan Administrator” means the Board or any committee of
the Board duly authorized to administer the Plan. The Plan Administrator may be, but is not required to be, the Compensation Committee of the Board. The Board may at any time administer the Plan, in whole or in part, notwithstanding that the Board
has previously appointed a committee to act as the Plan Administrator. 
 (s) “Qualifying Termination” means
either a Change in Control Termination or a Non-Change in Control Termination. 
 (t) “Resignation for Good
Reason” means a Participant’s resignation from all positions the Participant then holds with the Company, resulting in a Separation from Service, within thirty (30) days after the expiration of the cure period set forth below,
provided the Participant has given 

  
 2 

 
the Plan Administrator written notice of the occurrence of any of the following events taken without the Participant’s written consent within thirty (30) days after the first occurrence
of such event and the Company has not cured such event, to the extent curable, within thirty (30) days thereafter: (1) a material reduction in the Participant’s annual base salary; (2) a material adverse change in
Participant’s position causing such position to be of materially reduced status or responsibility; (3) relocation of the Participant’s principal place of employment to a place that increases the Participant’s one-way commute by
more than fifty (50) miles as compared to the Participant’s then-current principal place of employment immediately prior to such relocation; or (4) the failure of any successor-in-interest to assume a material obligation of the
Company under this Plan or material written contractual obligation to Participant, which (in either case) adversely affects the Participant. 

(u) “Separation from Service” means a “separation from service” within the meaning of Treasury
Regulations Section 1.409A-1(h), without regard to any alternative definition thereunder. 
 (v) “Severance
Multiplier” means: 
 (1) for a Participant who is the Chief Executive Officer of the Company at the time of the
Qualifying Termination, eighteen (18); and 
 (2) for a Participant who is not the Chief Executive Officer of the Company at the
time of the Qualifying Termination, six (6) plus one (1) for each full year of employment with the Company up to a maximum of twelve (12). 

(w) “Severance Period” means a period of months commencing on the date of a Participant’s Qualifying
Termination, with the number of months being equal to a Participant’s applicable Severance Multiplier. 
 (x) “Stock
Awards” means outstanding stock options and any other equity awards granted to a Participant from a Company plan. 
 3.
ELIGIBILITY FOR BENEFITS. 
 (a) Eligibility; Exceptions to Benefits. Subject to the
terms and conditions of the Plan, the Company will provide the benefits described in Section 4 to the affected Participant. The Plan does not provide for duplication (in whole or in part) of benefits with any other agreement or plan and any
payments under this Plan shall be reduced by any severance benefit payable to Participant under any other company plan, program or agreement. A Participant will not receive benefits under the Plan in the following circumstances, as determined by the
Plan Administrator, in its sole discretion: 
 (i) The Participant’s employment is terminated by either the Company or the
Participant for any reason other than a Qualifying Termination. 
 (ii) The Participant has not entered into the Employee
Proprietary Information and Inventions Agreement or any similar or successor document (the “Proprietary Information Agreement”). 

(iii) The Participant has failed to execute and allow to become effective the Release (as defined and described below) within sixty
(60) days following the Participant’s Separation from Service. 

  
 3 

 (iv) The Participant has failed to return all Company Property. For this purpose,
“Company Property” means all paper and electronic Company documents (and all copies thereof) created and/or received by the Participant during his or her period of employment with the Company and other Company materials and
property that the Participant has in his or her possession or control, including, without limitation, Company files, correspondence, emails, memoranda, notes, notebooks, drawings, records, plans, forecasts, reports, studies, analyses, proposals,
agreements, financial information, research and development information, sales and marketing information, operational and personnel information, specifications, code, software, databases, computer-recorded information, tangible property and
equipment (including, without limitation, leased vehicles, computers, computer equipment, software programs, facsimile machines, mobile telephones, servers), credit and calling cards, entry cards, identification badges and keys, and any materials of
any kind that contain or embody any proprietary or confidential information of the Company (and all reproductions thereof, in whole or in part). As a condition to receiving benefits under the Plan, a Participant must not make or retain copies,
reproductions or summaries of any such Company documents, materials or property and must make a diligent search to locate any such documents, property and information. If the Participant has used any personally owned computer, server, or e-mail
system to receive, store, review, prepare or transmit any Company confidential or proprietary data, materials or information, then within ten (10) business days after the Separation from Service, the Participant must provide the Company with a
computer-useable copy of all such information and then permanently delete and expunge such confidential or proprietary information from those systems. However, a Participant is not required to return his or her personal copies of documents
evidencing the Participant’s hire, termination, compensation, benefits and stock options and any other documentation received as a stockholder of the Company. A Participant’s failure to return Company Property that is neither confidential
nor material, such as an identification badge or calling card, will not, in and of itself, disqualify such Participant from receiving benefits under the Plan; provided, that any such items of Company Property are subsequently returned to the
Company upon request. 
 (v) The Participant has failed to cooperate fully with the Company in connection with its actual or
contemplated defense, prosecution, or investigation of any existing or future litigation, arbitrations, mediations, claims, demands, audits, government or regulatory inquiries, or other matters arising from events, acts, or failures to act that
occurred during the time period in which the Participant was employed by the Company (including any period of employment with an entity acquired by the Company). Such cooperation includes, without limitation, being available upon reasonable notice,
without subpoena, to provide accurate and complete advice, assistance and information to the Company, including offering and explaining evidence, providing truthful and accurate sworn statements, and participating in discovery and trial preparation
and testimony. As a condition of receiving benefits under the Plan, the Participant must also promptly send the Company copies of all correspondence (for example, but not limited to, subpoenas) received by the Participant in connection with any such
legal proceedings, unless the Participant is expressly prohibited by law from so doing. The Company will reimburse the Participant for reasonable out-of-pocket expenses incurred in connection with any such cooperation (excluding foregone wages,
salary, or other compensation) within thirty (30) days after the Participant’s timely presentation of appropriate documentation thereof, in accordance with the Company’s standard reimbursement policies and procedures, and will make
reasonable efforts to accommodate the Participant’s scheduling needs. 
 (b) Termination of Benefits. A Participant’s right
to receive benefits under the Plan will terminate immediately if, at any time prior to or during the period for which the Participant is receiving benefits under the Plan, the Participant, without the prior written approval of the Plan
Administrator: 
 (i) willfully breaches a material provision of the Participant’s Proprietary Information Agreement and/or any
obligations of confidentiality, non-solicitation, non-disparagement, no 

  
 4 

 
conflicts or non-competition provision set forth in any other agreement between the Company and a Participant (including, without limitation, the Participant’s employment agreement or offer
letter) or under applicable law; 
 (ii) encourages or solicits any of the Company’s then current employees to leave the
Company’s employ for any reason or interferes in any other manner with employment relationships at the time existing between the Company and its then current employees; or 

(iii) induces any of the Company’s then current clients, customers, suppliers, vendors, distributors, licensors, licensees, or
other third party to terminate their existing business relationship with the Company or interferes in any other manner with any existing business relationship between the Company and any then current client, customer, supplier, vendor, distributor,
licensor, licensee, or other third party. 
 4. PAYMENTS & BENEFITS. Except as may otherwise
be provided in a Participant’s Participation Notice, in the event of a Qualifying Termination, the Company will pay the Participant the Accrued Amounts, if any, on the date of such Qualifying Termination. In addition, subject to Sections 5 and
6 and a Participant’s continued compliance with the provisions of any agreement with the Company, including, without limitation, the Participant’s Proprietary Information Agreement, in the event of a Qualifying Termination, the Participant
shall be entitled to the payments and benefits described in this Section 4, subject to the terms and conditions of the Plan. 
 (a)
Cash Severance. 
 (i) Change in Control Termination. Upon a Change in Control Termination, the
Participant will receive as severance an amount equal to the product of (i) the sum of the Participant’s Monthly Base Salary and Monthly Annual Target Bonus, and (ii) the Participant’s applicable Severance Multiplier (the
“Change in Control Cash Severance”). The Change in Control Cash Severance will be paid in a single lump sum, less all applicable withholdings and deductions; provided, however, that no payments will be made
prior to the first business day to occur on or after the 60th day following the date of the Participant’s Qualifying Termination. 

(ii) Non-Change in Control Termination. Upon a Non-Change in Control Termination, the Participant will
receive as severance an amount equal to the product of (i) the sum of the Participant’s Monthly Base Salary and Monthly Annual Target Bonus, and (ii) the Participant’s applicable Severance Multiplier (the “Non-Change
in Control Cash Severance”). The Non-Change in Control Cash Severance will be paid in equal installments on the Company’s regular payroll schedule over the Severance Period, less all applicable withholdings and deductions;
provided, however, that no payments will be made prior to the first business day to occur on or after the 60th day following the date of the Participant’s Qualifying
Termination. On the first business day to occur on or after the 60th day following the date of the Participant’s Qualifying Termination, the Company will pay the Participant in a lump sum the
Non-Change in Control Cash Severance that the Participant would have received on or prior to such date under the original schedule but for the delay while waiting for the 60th day in compliance
with Section 409A of the Code and the effectiveness of the Release referenced in Section 5(a) below, with the balance of the Non-Change in Control Cash Severance being paid as originally scheduled. 

(b) COBRA Benefits. 

(i) If the Participant is eligible and has made the necessary elections for continuation coverage pursuant to COBRA under a health,
dental, or vision plan sponsored by the Company, the Company will pay, as and when due directly to the COBRA carrier, the COBRA premiums 

  
 5 

 
necessary to continue the COBRA coverage for the Participant and his or her eligible dependents until the earliest to occur of (i) the end of the applicable Severance Period, (ii) the
date on which the Participant becomes eligible for coverage under the group health insurance plans of a subsequent employer, and (iii) the date on which the Participant is no longer eligible for continuation coverage under COBRA (such period
from the date of the Qualifying Termination through the earliest of (i) through (iii), the “COBRA Payment Period”). 

(ii) Notwithstanding the foregoing, if at any time the Company determines, in its sole discretion, that the payment of COBRA premiums
hereunder is likely to result in a violation of the nondiscrimination rules of Section 105(h)(2) of the Code or any statute or regulation of similar effect (including, without limitation, the 2010 Patient Protection and Affordable Care Act, as
amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of providing the COBRA premiums, the Company will instead pay the Participant, on the first day of each month of the remainder of the COBRA Payment Period, a fully
taxable cash payment equal to the COBRA premiums for that month, subject to applicable tax withholdings and deductions. To the extent applicable, on the first business day to occur on or after the
60th day following the date of the Participant’s Qualifying Termination, the Company will make the first payment under this Section 4(b)(ii) in a lump sum equal to the aggregate amount
of payments that the Company would have paid through such date had such payments commenced on the Separation from Service through such 60th day, with the balance of the payments paid thereafter on
the original schedule. The Participant may, but is not obligated to, use such payments toward the cost of COBRA premiums. 
 (iii)
If the Participant becomes eligible for coverage under another employer’s group health plan or otherwise ceases to be eligible for COBRA during the applicable Severance Period, the Participant must immediately notify the Company of such
event, and all payments and obligations under this section 4(b) will cease. For purposes of this Section 4(b), references to COBRA also refer to analogous provisions of state law. Any applicable insurance premiums that are paid by the Company
will not include any amounts payable by the Participant under a Code Section 125 health care reimbursement plan, which are the sole responsibility of the Participant. 

(c) Accelerated Vesting. 

(i) Change in Control. Upon a Change in Control, the vesting and exercisability (if applicable) of outstanding and
unvested Stock Options that are held by the Participant on the effective date of the Change in Control will accelerate and become fully vested upon any of the following events: (i) any Stock Awards that do not remain in effect and are not
assumed or substituted with similarly equivalent options, restricted stock, stock appreciation rights, restricted stock units or the like following the closing of a Change in Control; (ii) if within one year following the closing of a Change of
Control there is a Change in Control Termination for Participant, and (iii) if the Participant is the Chief Executive Officer and remains an employee of the Company or its successor on the one-year anniversary of the closing of a Change in
Control. 
 5. CONDITIONS AND LIMITATIONS ON BENEFITS.

 (a) Release. To be eligible to receive any benefits under the Plan, a Participant must sign a general waiver and release in
substantially the form used by the Company from time to time. 
 (b) Prior Agreements; Certain Reductions. The Plan Administrator
will reduce a Participant’s benefits under the Plan by any other statutory severance obligations or contractual severance benefits, obligations for pay in lieu of notice, and any other similar benefits payable to the Participant by the Company
that are due in connection with the Participant’s Qualifying Termination and that are in the 

  
 6 

 
same form as the benefits provided under the Plan (e.g., equity award vesting credit). Without limitation, this reduction includes a reduction for any benefits required pursuant to (i) any
applicable legal requirement, including, without limitation, the Worker Adjustment and Retraining Notification Act (the “WARN Act”), (ii) a written employment, severance or equity award agreement with the Company,
(iii) any Company policy or practice providing for the Participant to remain on the payroll for a limited period of time after being given notice of the termination of the Participant’s employment, and (iv) any required salary
continuation, notice pay, statutory severance payment, or other payments either required by local law, or owed pursuant to a collective labor agreement, as a result of the termination of the Participant’s employment. The benefits provided under
the Plan are intended to satisfy, to the greatest extent possible, and not to provide benefits duplicative of, any and all statutory, contractual and collective agreement obligations of the Company in respect of the form of benefits provided under
the Plan that may arise out of a Qualifying Termination, and the Plan Administrator will so construe and implement the terms of the Plan. Reductions may be applied on a retroactive basis, with benefits previously provided being recharacterized as
benefits pursuant to the Company’s statutory or other contractual obligations. The payments pursuant to the Plan are in addition to, and not in lieu of, any unpaid salary, bonuses or employee welfare benefits to which a Participant may be
entitled for the period ending with the Participant’s Qualifying Termination. 
 (c) Mitigation. Except as otherwise
specifically provided in the Plan, a Participant will not be required to mitigate damages or the amount of any payment provided under the Plan by seeking other employment or otherwise, nor will the amount of any payment provided for under the Plan
be reduced by any compensation earned by a Participant as a result of employment by another employer or any retirement benefits received by such Participant after the date of the Participant’s termination of employment with the Company (except
as provided for in Section 5(b)). 
 (d) Indebtedness of Participants. To the extent permitted under applicable law, if a
Participant is indebted to the Company on the effective date of a Participant’s Qualifying Termination, the Company reserves the right to offset the payment of any benefits under the Plan by the amount of such indebtedness. Such offset will be
made in accordance with all applicable laws. The Participant’s execution of the Participation Notice constitutes knowing written consent to the foregoing. 

(e) Parachute Payments. 

(i) Except as otherwise expressly provided in an agreement between a Participant and the Company, if any payment or benefit the
Participant would receive in connection with a Change in Control from the Company or otherwise (a “Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and
(ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment will be equal to the Reduced Amount. The “Reduced Amount”
will be either (A) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax, or (B) the largest portion, up to and including the total, of the Payment, whichever amount ((A) or (B)),
after taking into account all applicable federal, state, provincial, foreign, and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Participant’s receipt, on an
after-tax basis, of the greatest economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting “parachute payments” is necessary so that the
Payment equals the Reduced Amount, reduction will occur in the following order: (1) reduction of cash payments; (2) cancellation of accelerated vesting of stock awards other than stock options; (3) cancellation of accelerated vesting
of stock options; and (4) reduction of other benefits paid to the Participant. Within any such category of Payments (that is, (1), (2), (3) or (4)), a reduction will occur first with respect to amounts that are not “deferred
compensation” within the meaning of Section 409A of the Code and then with respect to amounts that are “deferred compensation.” In the event that 

  
 7 

 
acceleration of vesting of stock award compensation is to be reduced, such acceleration of vesting will be cancelled in the reverse order of the date of grant of the Participant’s applicable
type of stock award (i.e., earliest granted stock awards are cancelled last). If Section 409A of the Code is not applicable by law to a Participant, the Company will determine whether any similar law in the Participant’s
jurisdiction applies and should be taken into account. 
 (ii) The professional firm engaged by the Company for general tax purposes
as of the day prior to the effective date of the Change in Control shall make all determinations required to be made under this Section 5(e). If the professional firm so engaged by the Company is serving as an accountant or auditor for the
individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized independent registered public accounting firm to make the determinations required hereunder. The Company shall bear all expenses with
respect to the determinations by such professional firm required to be made hereunder. Any good faith determinations of the professional firm made hereunder shall be final, binding and conclusive upon the Company and the Participant. 

6. TAX MATTERS. 

(a) Application of Code Section 409A. Notwithstanding anything herein to the contrary, (i) if at the time of
Participant’s termination of employment with the Company, the Participant is a “specified employee” as defined in Section 409A of the Code and the applicable guidance and regulations thereunder (collectively, “Section
409A”), and the deferral of the commencement of any payments or benefits otherwise payable hereunder as a result of such termination of employment is necessary in order to prevent any accelerated or additional tax under
Section 409A, then the Company will defer the commencement of the payment of any such payments or benefits hereunder (without any reduction in such payments or benefits ultimately paid or provided to Participant) until the first business day to
occur following the date that is six (6) months following Participant’s termination of employment with the Company (or the earliest date as is permitted under Section 409A); and (ii) if any other payments of money or other
benefits due to Participant hereunder could cause the application of an accelerated or additional tax under Section 409A, such payments or other benefits shall be deferred if deferral will make such payment or other benefits compliant under
Section 409A, or otherwise such payment or other benefits shall be restructured, to the extent possible, in a manner, determined by the Board, that does not cause such an accelerated or additional tax. In the event that payments under the Plan
are deferred pursuant to this Section 6 in order to prevent any accelerated tax or additional tax under Section 409A, then such payments shall be paid at the time specified under this Section 6 without any interest thereon. The
Company shall consult with Participant in good faith regarding the implementation of this Section 6; provided, that neither the Company nor any of its employees or representatives shall have any liability to Participant with respect
thereto. Notwithstanding anything to the contrary herein, to the extent required by Section 409A, a termination of employment shall not be deemed to have occurred for purposes of any provision of the Plan providing for the payment of amounts or
benefits upon or following a termination of employment unless such termination is also a “separation from service” within the meaning of Section 409A and, for purposes of any such provision of this Agreement, references to a
“resignation,” “termination,” “termination of employment” or like terms shall mean separation from service. For purposes of Section 409A, each payment made under the Plan shall be designated as a “separate
payment” within the meaning of the Section 409A. Notwithstanding anything to the contrary herein, except to the extent any expense, reimbursement or in-kind benefit provided pursuant to the Plan does not constitute a “deferral of
compensation” within the meaning of Section 409A, (A) the amount of expenses eligible for reimbursement or in-kind benefits provided to a Participant during any calendar year will not affect the amount of expenses eligible for
reimbursement or in-kind benefits provided to a Participant in any other calendar year; (B) the reimbursements for expenses for which a Participant is entitled to be reimbursed shall be made on or before the last day of the calendar year
following the calendar year in which the applicable expense is incurred; and (C) the right to payment or reimbursement or in-kind benefits hereunder may not be liquidated or exchanged for any other benefit. 

  
 8 

 (b) Withholding. All payments and benefits under the Plan will be subject to all
applicable deductions and withholdings, including, without limitation, obligations to withhold for federal, state, provincial, foreign and local income and employment taxes. 

(c) Tax Advice. By becoming a Participant in the Plan, the Participant agrees to review with the Participant’s own tax advisors
the federal, state, provincial, local, and foreign tax consequences of participation in the Plan. The Participant will rely solely on such advisors and not on any statements or representations of the Company or any of its agents. The Participant
understands that Participant (and not the Company) will be responsible for his or her own tax liability that may arise as a result of becoming a Participant in the Plan. 

7. REEMPLOYMENT. In the event of a Participant’s reemployment by the Company during the period of time in respect
of which severance benefits have been provided (that is, benefits as a result of a Qualifying Termination), the Company, in its sole and absolute discretion, may require such Participant to repay to the Company all or a portion of such severance
benefits as a condition of reemployment. 
 8. CLAWBACK; RECOVERY. All payments and severance benefits
provided under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company’s
securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in the Participation
Notice, as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause. No recovery of compensation
under such a clawback policy will be an event giving rise to Resignation for Good Reason, constructive termination, or any similar term under any plan of or agreement with the Company. 

9. RIGHT TO INTERPRET PLAN; AMENDMENT AND
TERMINATION. 
 (a) Exclusive Discretion. The Plan Administrator shall have the exclusive discretion and authority
to establish rules, forms, and procedures for the administration of the Plan and to construe and interpret the Plan and to decide any and all questions of fact, interpretation, definition, computation or administration arising in connection with the
operation of the Plan, including, but not limited to, the eligibility to participate in the Plan and amount of benefits paid under the Plan. The rules, interpretations, computations and other actions of the Plan Administrator shall be binding and
conclusive on all persons. 
 (b) Amendment or Termination. The Company reserves the right to amend or terminate the Plan, any
Participation Notice issued pursuant to the Plan or the benefits provided hereunder at any time; provided, however, that no such amendment or termination will apply to any Participant who would be adversely affected by such amendment or
termination unless such Participant consents in writing to such amendment or termination. Any action amending or terminating the Plan or any Participation Notice will be in writing and executed by a duly authorized officer of the Company. 

  
 9 

 10. NO IMPLIED EMPLOYMENT
CONTRACT. 
 The Plan shall not be deemed (i) to give any employee or other person any right to be retained in the
employ of the Company or (ii) to interfere with the right of the Company to discharge any employee or other person at any time, with or without cause, which right is hereby reserved. 

11. ERISA; LEGAL CONSTRUCTION. 

This Plan is intended to be governed by and shall be construed in accordance with the Employee Retirement Income Security Act of 1974
(“ERISA”) and, to the extent not preempted by ERISA, the laws of the State of Washington. A statement of ERISA rights, and other Plan information is set forth in Exhibit B attached hereto and incorporated by reference.

 12. GENERAL PROVISIONS. 

(a) Notices. Any notice, demand or request required or permitted to be given by either the Company or a Participant pursuant to the
terms of the Plan will be in writing and will be deemed given when delivered personally, when received electronically (including email addressed to the Participant’s Company email account and to the Company email account of the Company’s
Chief Executive Officer), or deposited in the U.S. Mail, First Class with postage prepaid, and addressed to the parties, in the case of the Company, at the address set forth in Section 14(d), in the case of a Participant, at the address as set
forth in the Company’s employment file maintained for the Participant as previously furnished by the Participant or such other address as a party may request by notifying the other in writing. 

(b) Transfer and Assignment. The rights and obligations of a Participant under the Plan may not be transferred or assigned without the
prior written consent of the Company. The Plan will be binding upon any surviving entity resulting from a Change in Control and upon any other person who is a successor by merger, acquisition, consolidation or otherwise to the business formerly
carried on by the Company without regard to whether or not such person or entity actively assumes the obligations hereunder. 
 (c)
Waiver. Any party’s failure to enforce any provision or provisions of the Plan will not in any way be construed as a waiver of any such provision or provisions, nor prevent any party from thereafter enforcing each and every other provision
of the Plan. The rights granted to the parties herein are cumulative and will not constitute a waiver of any party’s right to assert all other legal remedies available to it under the circumstances. 

(d) Severability. Should any provision of the Plan be declared or determined to be invalid, illegal or unenforceable, the validity,
legality and enforceability of the remaining provisions will not in any way be affected or impaired. 
 (e) Section Headings. Section
headings in the Plan are included only for convenience of reference and will not be considered part of the Plan for any other purpose. 

  
 10 

 EXHIBIT A 

ALDER BIOPHARMACEUTICALS, INC. 

EXECUTIVE SEVERANCE BENEFIT PLAN 

PARTICIPATION NOTICE 

To: Alder BioPharmaceuticals Human Resources Director 

Date:                     

Alder BioPharmaceuticals, Inc. (the “Company”) has adopted the Alder BioPharmaceuticals, Inc. Executive Severance
Benefit Plan (the “Plan”). The Company is providing you this Participation Notice to inform you that you have been designated as a Participant in the Plan. A copy of the Plan document is attached to this Participation Notice.
The terms and conditions of your participation in the Plan are as set forth in the Plan and this Participation Notice, which together constitute the Summary Plan Description for the Plan. 

You understand that by accepting your status as a Participant in the Plan, [except as expressly stated in the Plan] you are waiving your
rights to receive any severance benefits on any type of termination of employment under any other contract or agreement with the Company. 

You also understand that by accepting your status as a Participant in the Plan, your stock options that have been considered to be
“incentive stock options” prior to the date hereof may cease to qualify as “incentive stock options” as a result of the vesting acceleration benefit provided in the Plan. By accepting participation, you represent that you have
either consulted your personal tax or financial planning advisor about the tax consequences of your participation in the Plan, or you have knowingly declined to do so. 

Please return a signed copy of this Participation Notice to the Company’s Human Resources Director at the Company’s offices and
retain a copy of this Participation Notice, along with the Plan document, for your records. 
  

			
	 ALDER BIOPHARMACEUTICALS, INC.:

	
	  

	(Signature)
		
	 By:
	 	  

		
	 Title:
	 	  

	
	 PARTICIPANT:

	
	  

	(Signature)
		
	 By:
	 	  

 EXHIBIT B 

MATTERS RELATED TO PLAN CLAIMS, ERISA RIGHTS
AND OTHER INFORMATION 
  

	 	I.	CLAIMS, INQUIRIES AND APPEALS. 

(f) Applications for Benefits and Inquiries. Any application for benefits, inquiries about the Plan or inquiries about present or future
rights under the Plan must be submitted to the Plan Administrator in writing by an applicant (or his or her authorized representative). The Plan Administrator is: 

Alder BioPharmaceuticals, Inc. 

11804 North Creek Parkway South 

Bothell, WA 98011 
 (g) Denial
of Claims. In the event that any application for benefits is denied in whole or in part, the Plan Administrator must provide the applicant with written or electronic notice of the denial of the application, and of the applicant’s right to
review the denial. Any electronic notice will comply with the regulations of the U.S. Department of Labor. The notice of denial will be set forth in a manner designed to be understood by the applicant and will include the following: 

(1) the specific reason or reasons for the denial; 

(2) references to the specific Plan provisions upon which the denial is based; 

(3) a description of any additional information or material that the Plan Administrator needs to complete the review and an
explanation of why such information or material is necessary; and 
 (4) an explanation of the Plan’s review procedures and the
time limits applicable to such procedures, including a statement of the applicant’s right to bring a civil action under Section 502(a) of ERISA following a denial on review of the claim, as described in Section 9(d) below. 

This notice of denial will be given to the applicant within ninety (90) days after the Plan Administrator receives the application,
unless special circumstances require an extension of time, in which case, the Plan Administrator has up to an additional ninety (90) days for processing the application. If an extension of time for processing is required, written notice of the
extension will be furnished to the applicant before the end of the initial ninety (90) day period. 
 This notice of extension will
describe the special circumstances necessitating the additional time and the date by which the Plan Administrator is to render its decision on the application. 

(h) Request for a Review. Any person (or that person’s authorized representative) for whom an application for benefits is denied,
in whole or in part, may appeal the denial by submitting a request for a review to the Plan Administrator within sixty (60) days after the application is denied. A request for a review shall be in writing and shall be addressed to: 

Alder BioPharmaceuticals, Inc. 

11804 North Creek Parkway South 

Bothell, WA 98011 

 A request for review must set forth all of the grounds on which it is based, all facts in support of the request
and any other matters that the applicant feels are pertinent. The applicant (or his or her representative) shall have the opportunity to submit (or the Plan Administrator may require the applicant to submit) written comments, documents, records, and
other information relating to his or her claim. The applicant (or his or her representative) shall be provided, upon request and free of charge, reasonable access to, and copies of, all documents, records and other information relevant to his or her
claim. The review shall take into account all comments, documents, records and other information submitted by the applicant (or his or her representative) relating to the claim, without regard to whether such information was submitted or considered
in the initial benefit determination. 
 (i) Decision on Review. The Plan Administrator will act on each request for review within
sixty (60) days after receipt of the request, unless special circumstances require an extension of time (not to exceed an additional sixty (60) days), for processing the request for a review. If an extension for review is required, written
notice of the extension will be furnished to the applicant within the initial sixty (60) day period. This notice of extension will describe the special circumstances necessitating the additional time and the date by which the Plan Administrator
is to render its decision on the review. The Plan Administrator will give prompt, written or electronic notice of its decision to the applicant. Any electronic notice will comply with the regulations of the U.S. Department of Labor. In the event
that the Plan Administrator confirms the denial of the application for benefits in whole or in part, the notice will set forth, in a manner calculated to be understood by the applicant, the following: 

(1) the specific reason or reasons for the denial; 

(2) references to the specific Plan provisions upon which the denial is based; 

(3) a statement that the applicant is entitled to receive, upon request and free of charge, reasonable access to, and copies of, all
documents, records and other information relevant to his or her claim; and 
 (4) a statement of the applicant’s right to bring
a civil action under Section 502(a) of ERISA. 
 (j) Rules and Procedures. The Plan Administrator will establish rules and
procedures, consistent with the Plan and with ERISA, as necessary and appropriate in carrying out its responsibilities in reviewing benefit claims. The Plan Administrator may require an applicant who wishes to submit additional information in
connection with an appeal from the denial of benefits to do so at the applicant’s own expense. 
 (k) Exhaustion of Remedies. No
legal action for benefits under the Plan may be brought until the applicant (i) has submitted a written application for benefits in accordance with the procedures described by Section 9(a) above, (ii) has been notified by the Plan
Administrator that the application is denied, (iii) has filed a written request for a review of the application in accordance with the appeal procedure described in Section I(c) above, and (iv) has been notified that the Plan Administrator
has denied the appeal. Notwithstanding the foregoing, if the Plan Administrator does not respond to a Eligible Employee’s claim or appeal within the relevant time limits specified in this Section 9, the Eligible Employee may bring legal
action for benefits under the Plan pursuant to Section 502(a) of ERISA. 

	 	II.	BASIS OF PAYMENTS TO AND FROM PLAN. 

The Plan shall be unfunded, and all cash payments under the Plan shall be paid only from the general assets of the Company. 

 

	 	III.	OTHER PLAN INFORMATION. 

 (a) Employer
and Plan Identification Numbers. The Employer Identification Number assigned to the Company (which is the “Plan Sponsor” as that term is used in ERISA) by the Internal Revenue Service is
                    . The Plan Number assigned to the Plan by the Plan Sponsor pursuant to the instructions of the Internal Revenue Service
is             . 
 (b) Ending Date for Plan’s Fiscal
Year. The date of the end of the fiscal year for the purpose of maintaining the Plan’s records is December 31. 
 (c) Agent
for the Service of Legal Process. The agent for the service of legal process with respect to the Plan is: 
 Alder BioPharmaceuticals,
Inc. 
 11804 North Creek Parkway South 

Bothell, WA 98011 
 In addition, service of legal
process may be made upon the Plan Administrator. 
 (d) Plan Sponsor and Administrator. The “Plan Sponsor” and the
“Plan Administrator” of the Plan is: 
 Randall Schatzman 

Alder BioPharmaceuticals, Inc. 

11804 North Creek Parkway South 

Bothell, WA 98011 
 The Plan Sponsor’s and
Plan Administrator’s telephone number is (425) 205-2910. The Plan Administrator is the named fiduciary charged with the responsibility for administering the Plan. 
  

	 	IV.	STATEMENT OF ERISA RIGHTS. 

 Eligible
Employees in this Plan (which is a welfare benefit plan sponsored by Alder BioPharmaceuticals, Inc.) are entitled to certain rights and protections under ERISA. If you are an Eligible Employee, you are considered a participant in the Plan and, under
ERISA, you are entitled to: 
 (e) Receive Information About Your Plan and Benefits 

(1) Examine, without charge, at the Plan Administrator’s office and at other specified locations, such as worksites, all documents
governing the Plan and a copy of the latest annual report (Form 5500 Series), if applicable, filed by the Plan with the U.S. Department of Labor and available at the Public Disclosure Room of the Employee Benefits Security Administration; 

(2) Obtain, upon written request to the Plan Administrator, copies of documents governing the operation of the Plan and copies of the
latest annual report (Form 5500 Series), if applicable, and an updated (as necessary) Summary Plan Description. The Administrator may make a reasonable charge for the copies; and 

 (3) Receive a summary of the Plan’s annual financial report, if applicable. The Plan
Administrator is required by law to furnish each participant with a copy of this summary annual report. 
 (f) Prudent Actions by Plan
Fiduciaries. In addition to creating rights for Plan participants, ERISA imposes duties upon the people who are responsible for the operation of the employee benefit plan. The people who operate the Plan, called “fiduciaries” of the
Plan, have a duty to do so prudently and in the interest of you and other Plan participants and beneficiaries. No one, including your employer, your union or any other person, may fire you or otherwise discriminate against you in any way to prevent
you from obtaining a Plan benefit or exercising your rights under ERISA. 
 (g) Enforce Your Rights. If your claim for a Plan benefit
is denied or ignored, in whole or in part, you have a right to know why this was done, to obtain copies of documents relating to the decision without charge, and to appeal any denial, all within certain time schedules. 

Under ERISA, there are steps you can take to enforce the above rights. For instance, if you request a copy of Plan documents or the latest
annual report from the Plan, if applicable, and do not receive them within thirty (30) days, you may file suit in a Federal court. In such a case, the court may require the Plan Administrator to provide the materials and pay you up to $110 a
day until you receive the materials, unless the materials were not sent because of reasons beyond the control of the Plan Administrator. 

If you have a claim for benefits which is denied or ignored, in whole or in part, you may file suit in a state or Federal court. 

If you are discriminated against for asserting your rights, you may seek assistance from the U.S. Department of Labor, or you may file suit
in a Federal court. The court will decide who should pay court costs and legal fees. If you are successful, the court may order the person you have sued to pay these costs and fees. If you lose, the court may order you to pay these costs and fees,
for example, if it finds your claim is frivolous. 
 (h) Assistance with Your Questions. If you have any questions about the Plan,
you should contact the Plan Administrator. If you have any questions about this statement or about your rights under ERISA, or if you need assistance in obtaining documents from the Plan Administrator, you should contact the nearest office of the
Employee Benefits Security Administration, U.S. Department of Labor, listed in your telephone directory or the Division of Technical Assistance and Inquiries, Employee Benefits Security Administration, U.S. Department of Labor, 200 Constitution
Avenue N.W., Washington, D.C. 20210. You may also obtain certain publications about your rights and responsibilities under ERISA by calling the publications hotline of the Employee Benefits Security Administration.<![CDATA[Master Product Development & Clinical Supply Agreement]]>

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
 EXHIBIT 10.24 

Master Product Development and Clinical Supply Agreement 

This MASTER PRODUCT DEVELOPMENT AND CLINICAL
SUPPLY AGREEMENT (the “Agreement”) is entered into as of the 21st day of March, 2011 (“Effective
Date”) by and between ALDER BIOPHARMACEUTICALS, INC., a corporation organized and existing under the laws of Delaware, with its principal offices located at 11804 North Creek Parkway South, Bothell, WA 98011
(“Client”), and ALTHEA TECHNOLOGIES, INC., a Delaware corporation, with a place of business located at 11040 Roselle Street, San Diego, CA 92121
(“Althea”). 
 WHEREAS Client is a biopharmaceutical company focused on the discovery, development and
commercialization of products for human therapeutic use, including the Client Products (defined below), and has formulations and/or know-how related to the Client Products; 

WHEREAS Althea has the expertise and the manufacturing facility suitable for the Production (defined below) of Client Products; and

 WHEREAS, Client wishes to have Althea Produce Client Products, and Althea wishes to Produce Client Products for Client,
subject to and in accordance with the terms and conditions of this Agreement and the individual Project Work Agreements (defined below) entered into by the parties from time to time. 

NOW, THEREFORE, in consideration of the premises and the undertakings, terms, conditions and covenants set forth below, the parties
hereto agree as follows: 
  

	1.	DEFINITIONS. 

 1.1 “Affiliate” of a party hereto shall mean any
entity that controls or is controlled by such party, or is under common control with such party. For purposes of this definition, an entity shall be deemed to control another entity if it owns or controls, directly or indirectly, at least 50% of the
voting equity of another entity (or other comparable interest for an entity other than a corporation) or otherwise possesses the ability to control the management of such other entity 

1.2 “Alder Technology” means all proprietary technical information, know-how (whether or not patentable) and other
Intellectual Property (including, without limitation, processes, together with associated data and information) which is owned or possessed by Alder and associated with the [***] (including without limitation the Client Product). Alder Technology
includes specifically and without limitation the information, know-how, registration data, experience, instructions, standards, methods, test and trial results, manufacturing processes, hazard assessments, quality control standards, formulae,
specifications, storage data, samples, drawings, designs, analytical methods, validation reports of analytical methods and all other relevant information relating to the Client Product that is supplied and transferred by Client to Althea to
facilitate the Manufacture of the Client Product by Althea pursuant to this Agreement. 
 1.3 “Althea SOPs” or
“SOPs” shall mean Althea’s Standard Operating Procedures, and any other standard operating procedures jointly agreed upon in writing by the parties. Althea shall customize Althea SOPs on a Product specific basis, as necessary, for
Production of Client Product. Client will review [***] each Client Product-specific Althea SOP prior to Production of Client Product, and will review [***] any subsequent revisions to these Althea SOPs prior to use of such revised Althea SOPs.

  

					
	ALTHEA & ALDER CONFIDENTIAL	  	1	  	FINAL

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 1.4 “Applicable Jurisdiction” shall mean the United States of America
and any Foreign Jurisdictions which are expressly listed in a PWA as “Applicable Jurisdictions” for such PWA. Althea warrants that it is has the necessary capabilities and facilities and any general licenses required for cGMP manufacturing
of pharmaceuticals and biologics in the United States of America, the EU, the EU Member States and EEA EFTA States, and Japan. 

1.5 “Batch” shall mean a specific quantity of Client Product comprising a number of units mutually agreed upon between
Client and Althea, and that (a) is intended to have uniform character and quality, within specified limits, and (b) is Produced according to a single manufacturing order during the same cycle of manufacture. 

1.6 “Bulk Drug” or “BDS” shall mean the active pharmaceutical ingredient of Client Product, in bulk
form, and refers to BDS that has been or is to be Produced for Client by Althea pursuant to this Agreement. For clarity, the parties agree that the term “Bulk Drug”, when used in the definitions of “Drug Product” and
“Finished Product” or when otherwise used for purposes of subsequent Production or Processing of Bulk Drug under this Agreement, refers only to Bulk Drug that both has been Produced for Client by Althea pursuant to this Agreement and has
not left Althea’s custody or control pending additional Production or Processing (i.e., Bulk Drug that has not been delivered by Althea to Client or its designee). 

1.7 “cGMP” shall mean the regulatory requirements for current good manufacturing practices and general biologics
products standards, including the United States’ current Good Manufacturing Practices pursuant to the U.S. Federal Food, Drug, and Cosmetic Act, as amended (21 U.S.C. Sect. 301 et seq.) (“FD&C Act”), and relevant
regulations found in Title 21 of the U.S. Code of Federal Regulations (including Parts 210, 211, 600 and 611), and the European Union’s current Good Manufacturing Practices pursuant to the European Commission in Directive 91/356/EEC, as amended
by 2003/94/EC, and the Guide to Good Manufacturing Practice (Volume 4 of “The rules governing medicinal products in the European Union”), and the other applicable regulatory guidance documents (including without limitation FDA’s
Guidance for Industry Q7A Good Manufacturing Practice Guide For Active Pharmaceutical Ingredients, and Annex 18 to the European Union’s Guide to Good Manufacturing Practices) and current industry practices promulgated by the applicable
Regulatory Authorities, and any comparable laws, rules or regulations of any Foreign Jurisdiction which is specified in a PWA, as each may be amended from time to time. For clarity, the parties agree that a Foreign Jurisdiction’s cGMP
requirements shall apply only if such Foreign Jurisdiction is listed in the applicable PWA as an Applicable Jurisdiction for that PWA. 

1.8 “Cancellation Fees” shall have the meaning set forth in Section 3.3. 

1.9 “Certificate of Analysis” shall mean a certificate of analysis that confirms that a Batch meets the Specifications

 1.10 “Client Information and Materials” shall mean Client’s Confidential Information, Client’s
Inventions (including Alder Technology Inventions), Alder Technology, Client’s Intellectual Property, the cell line(s) supplied to Althea directly or indirectly by Client for Client Product, any related proprietary reference standards, the
master and working cell bank(s) supplied to Althea directly or indirectly by Client or Produced by Althea under this Agreement for Client Product, Client Supplied Components. 

1.11 “Client Product” or “Product” shall mean the proprietary biological pharmaceutical product(s) to be
Produced by Althea under this Agreement, and refers specifically to the Client Product identified in the related PWA. When the context requires, the term “Client Product” also means the tangible forms of Client Product which are or are to
be Produced by Althea under this Agreement, 

  

					
	ALTHEA & ALDER CONFIDENTIAL	  	2	  	FINAL

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 
including Bulk Drug Substance, Drug Product, and/or Finished Product, and also including all in-process intermediates, samples or modifications thereof or thereto. For the avoidance of doubt,
“Client Product” under this Agreement is limited to Bulk Drug Substance Produced under this Agreement, Drug Product Produced from such Bulk Drug Substance, and/or Finished Product Produced from such Bulk Drug Substance, and for any other
Client product(s) or production (e.g., fill-finish services for drug product manufactured for Client by a third party), such product(s) or production shall be governed by the pre-existing agreement referenced in Section 15.2 and the related
“Project Plan” (as defined therein) between the parties. 
 1.12
“Components” shall mean all components and raw materials used or to be used by Althea in Production of Client Product under this Agreement. All Components are listed in or will be agreed
to by the parties pursuant to and in accordance with the related PWA, and are or will be identified either as Components to be supplied by Client or its vendors (“Client Supplied Components”) or Components to be supplied by
Althea or its vendors (“Althea Supplied Components”). 
 1.13 “Confidential
Information” shall have the meaning set forth in Section 9.1 
 1.14 “Conforming” shall mean Client Product
(Bulk Drug, Drug Product, or Finished Product) that conforms to the warranties set forth in Section 11.2.2 of this Agreement. 

1.15 “Drug Product” shall mean Bulk Drug which has been formulated, compounded, filled into containers (without
Labeling). 
 1.16 “Facility” shall mean Althea’s facility located at [***], and, as applicable, shall
mean the specific building or plant set forth in the related PWA. 
 1.17 “FDA” shall mean the United States
Food and Drug Administration or any successor entity thereto. 
 1.18 “Finished Product” shall mean Bulk Drug which
has been formulated, compounded, filled into containers, and Labeled, and placed in final packaging. 
 1.19 “Foreign
Jurisdiction” shall mean any jurisdiction other than the United States of America. 
 1.20 “Invention”
shall mean any invention, innovation, improvement, development, discovery, trade secret, method, know-how, process, technique or the like, whether or not written or otherwise fixed in any form or medium, regardless of the media on which contained,
and whether or not patentable or copyrightable, and, as the context requires, refers to Inventions which are conceived, reduced to practice, or created in the course of or resulting from this Agreement. 

1.21 “Intellectual Property” shall mean all rights, privileges and priorities provided under applicable supranational,
international, national, federal, state or local law, rule, regulation, statute, ordinance, order, judgment, decree, permit, franchise, license, or other government restriction or requirement of any kind relating to intellectual property, whether
registered or unregistered, and whether patentable, copyrightable or trademarkable or not, in any country, including without limitation: (a) all (i) patents and patent applications (including any patent that in the future may issue in
connection therewith and all divisions, continuations, continuations-in-part, extensions, additions, registrations, confirmations, reexaminations, supplementary protection certificates, renewals or reissues thereto or thereof), (ii) copyrights
and copyrightable works, including reports, software, databases and related items, and (iii) trademarks, service marks, trade names, brand names, product names, corporate names, logos and trade dress, the goodwill of any business symbolized
thereby, and all common-law rights relating thereto; and 

  

					
	ALTHEA & ALDER CONFIDENTIAL	  	3	  	FINAL

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 
(b) all registrations, applications, recordings, rights of enforcement, rights of recovery based on past infringement and any and all claims of action related thereto and licenses or other
similar agreements related to the foregoing. 
 1.22 “Labeling” shall mean all labels and other written, printed, or
graphic matter upon: (i) Client Product or any container, carton, or wrapper utilized with Client Product or (ii) any written material accompanying Client Product, or, as the context requires, shall mean the labeling services to be
performed by Althea under this Agreement, as the context requires 
 1.23 “Legal Requirements” means all
laws, rules, regulations, ordinances, guidance, guidelines, and standards of any supranational, international, national, federal, state, or local governmental authority which are applicable to the circumstances in which the term “Legal
Requirements” is used herein, including without limitation (a) cGMP, and, as applicable, current Good Laboratory Practices (as set forth in 21 CFR Part 58), (b) the regulations and regulatory guidance promulgated by the FDA and the
EMA (and, subject to express prior written agreement of the parties, other applicable Regulatory Authorities), and (c) all laws and regulations requiring permits, licenses, filings or certifications with respect to Alder, Althea, the Althea
Facility, or the Production of Product or performance of other services pursuant to this Agreement. For clarity, the parties agree that a Foreign Jurisdiction’s Legal Requirements shall apply only if such Foreign Jurisdiction is expressly
listed in the applicable PWA as an “Applicable Jurisdiction” for that PWA. 
 1.24 [***] 

1.25 “Master Batch Record” ( or “MBR”) shall mean the formal set of instructions for
Production of Client Product. The MBR shall be developed and maintained in Althea’s standard format by Althea, using Client’s master formula and technical support. 

1.26 “Production” or “Produce” shall mean all steps and activities performed or to be performed by
Althea under this Agreement to produce Client Product, as set forth in the related PWA, including, without limitation and as applicable, the manufacturing, formulation, filling, finishing, packaging, inspection, Labeling, testing, quality control,
and release, shipping and storage of Client Product. 
 1.27 “Production Process” or
“Process” shall mean the processes, methods, tests and techniques for Producing the Client Product. The Process may be changed from time to time by agreement of the parties and in accordance with the Quality Agreement. Althea shall
not change the Process except at the request of or with permission from Alder. 
 1.28 “Project Work
Agreements” or “PWAs” shall mean the project work agreements between the parties that reference this Agreement. For each Client Product for which Althea performs Production services, the parties shall execute one or more
PWAs, in a form acceptable to the parties and substantially in the form attached hereto as Appendix A. When and if executed by both parties, each PWA (including all Exhibits, Schedules and other Attachments thereto) shall be deemed attached to and
shall be incorporated by this reference into this Agreement. 
 1.29 “Purchase Price” shall mean the amount
to be paid by Client as specified in the related PWA. 
 1.30 “Quality Agreement” shall mean the written quality
agreement between Althea and Client of even date herewith that defines the quality roles and responsibilities of each party in connection with Production of Client Product and which refers to this Agreement. The Quality Agreement is incorporated
into this Agreement by this reference. 

  

					
	ALTHEA & ALDER CONFIDENTIAL	  	4	  	FINAL

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 1.31 “Regulatory Authority” shall mean any agency or authority
responsible for regulation of Client Product in the United States or any foreign regulatory jurisdiction. For clarity, the parties agree that a Foreign Jurisdiction’s Regulatory Authority shall be applicable to a PWA only if such Foreign
Jurisdiction is expressly listed in the applicable PWA as an Applicable Jurisdiction. 
 1.32 “Released Executed Batch
Record” shall mean the completed batch record executed by Althea and associated deviation reports, investigation reports, and Certificates of Analysis created for each Batch of Client Product 

133 “Services” means the services performed or to be performed by Althea under this Agreement, including Production. 

1.33 “Specifications” shall mean the applicable specifications for a Client Product, including, as applicable, the
specifications for Bulk Product, Drug Product, or Finished Product, set forth in the related PWA and the applicable MBR or, as the context requires, the applicable specifications for the Components. 

1.34 “Term” shall have the meaning provided in Section 3.1. 

1.35 “third party” shall mean any person(s) or entity(ies) other than Althea or Client. 

 

	2.	DEVELOPMENT AND PRODUCTION OF CLIENT PRODUCT. 

 2.1 Production: Subject to
execution of this Agreement and the Quality Agreement, upon execution of each PWA (subject to satisfaction of any conditions precedent that may be set forth in such PWA), Althea shall perform the Services set forth therein in accordance with this
Agreement, the Quality Agreement and such PWA, in compliance with all applicable Legal Requirements, and pursuant to the timeline set forth in such PWA. In the event of conflict between this Agreement and any PWA, the provisions of this Agreement
shall control, unless the PWA states an express intent to control or supersede this Agreement. All Client Product supplied to Client hereunder shall be [***]. 

2.2 Documentation: The Master Batch Record shall be reviewed and approved by Althea and by Client prior to commencement of Production.
Any material change to an approved Master Batch Record will be reviewed and approved by Althea and by Client prior to said change being implemented. Each Batch of Client Product shall be Produced by using a copy of the Master Batch Record. Each copy
of the Master Batch Record for such Batch of Client Product shall be assigned a unique Batch number. Any deviation from the Production Process specified in the Master Batch Record must be documented in the copy of the Master Batch Record for that
Batch. Althea shall provide Client with the Released Executed Batch Record and any other Production documentation customarily supplied by contract manufacturers together with any other documentation expressly required under this Agreement, the
Quality Agreement or the related PWA, in a form reasonably suitable for Client’s submission to the FDA or other Regulatory Authorities. 

2.3 Delays in Production: If Althea is unable to, or believes it is likely that it will be unable to, fulfill any particular Production
commitment on the applicable date set forth in the related PWA, including without limitation as a result of a force majeure event, then Althea shall immediately notify Client in writing as to the reason for the delay, and provide an indication of
the likely duration of the delay, and use commercially reasonable efforts to continue Production, recover lost time and support all timelines and deadlines as established in such PWA. As appropriate, [***]. 

  

					
	ALTHEA & ALDER CONFIDENTIAL	  	5	  	FINAL

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 2.4 Vendor and Supplier Audit and Certification; Subcontractors: 

2.4.1 As set forth in more detail in the Quality Agreement, Client shall qualify and audit all vendors and suppliers of Client Supplied
Components, and Althea shall qualify and audit all vendors and suppliers of Althea Supplied Components, each of whom must be set forth in the related PWA or otherwise approved in writing by Client. 

2.4.2 Althea shall not subcontract or delegate its obligation to perform any portion of the Production services without, in each case,
the prior written approval of Alder and, if applicable, the relevant Regulatory Authorities. Althea shall qualify and audit all subcontractors in accordance with the Quality Agreement. Althea shall cause its subcontractors to comply with, and to be
bound by provisions which are comparable to, the applicable terms of this Agreement, the applicable PWAs, and the Quality Agreement, including without limitation the audit, confidentiality and non-use, inventions and intellectual property, and
quality control provisions. Althea will be liable for and fully responsible to Client for any portion of the Production services performed by any subcontractor or consultant to the same extent as if such portion of the services was performed
directly by Althea. 
 2.5 Delivery Terms: Althea shall ship all Client Product to Client or, at Client’s instructions,
to Clients designated consignee. All shipments shall be delivered [***] and shipped by a common carrier designated by Client, [***]. [***]. All shipping instructions of Client shall be accompanied by the name and address of the consignee and the
shipping date. At the request of Client, Althea shall store particular lots of Client Product for up to [***] at no additional cost and, thereafter, at Client’s expense at the storage fee set forth in the related PWA or, if none, at
Althea’s usual and customary rates. Althea shall store all Client Product under conditions that comply with the applicable Specifications, any applicable requirements set forth in the Quality Agreement, and any other reasonable written
instructions of Client. Following delivery of Client Product, with respect to any related remaining Client Supplied Components (other than and not including Client Supplied Components which are intended for subsequent use by Althea for Client’s
benefit), Althea will request and follow instructions from Client as to whether Althea should ship to Client or Client’s designated consignee, store or dispose of such related remaining Client Supplied Components, and, if Althea does not
receive instructions from Client within [***] of such request, Althea shall [***]; provided, however, that if Althea is storing such items pursuant to this Section 2.5 and wishes to discontinue storing such items, Althea
shall give Client at least [***] notice and will request and follow instructions from Client as to whether Althea should ship to Client or Client’s designated consignee or dispose of such items, and, if Althea does nor receive instructions from
Client within [***] of such request, Althea shall [***]. 
 2.6 Exporter of Record: Client shall be the exporter of record for
any Client Product shipped out of the United States, as Client remains the owner of the Client Product. Client [***]. Client shall be responsible for obtaining [***] any licenses, clearances or other governmental authorization(s) necessary for the
exportation of any Client Product from the United States. Client shall select and pay the freight forwarder [***]. [***] 
 2.7
Supply of Components; Material Safety Data Sheets: 
 2.7.1 Alder will timely procure, [***], and timely provide to Althea
sufficient quantities of Client Supplied Components as required for the Production of Client Product, in accordance with the related PWA. Althea will timely procure, [***], all Althea Supplied Components as required for the Production of Client
Product. Althea shall maintain, store and perform testing and evaluation of all Components, including Client Supplied Components, as required by the applicable Specifications and cGMP and otherwise in accordance with the Quality Agreement and
applicable SOPs. As between the parties, Client is the sole and exclusive owner of all Client Supplied Components and all other Client Information and Materials. Althea shall use the Client Supplied Components and all other Client Information and
Materials solely to perform its obligations under this Agreement, the related PWAs and the Quality Agreement and for no other purpose. 

  

					
	ALTHEA & ALDER CONFIDENTIAL	  	6	  	FINAL

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 2.7.2 Client shall provide Althea a material safety data sheet for Client Supplied
Components and for Client Product and Althea shall materially conform to established safety practices and procedures set forth therein. Althea shall store and handle Client Product and all Components in accordance with and as required by, as
applicable, the MSDS, the MBR and all applicable Legal Requirements. Althea is under no obligation to produce products which are classified as [***], all of which generally require [***]. Althea understands and agrees that the Client Product may
have unpredictable and unknown biological and/or chemical properties and should be used with caution [***]. Althea shall immediately notify Client of any unusual health or environmental occurrence relating to Client Product, including, but not
limited to [***]. Althea agrees to advise Client immediately of any safety or toxicity problems of which it becomes aware regarding the Client Product. 

2.8 Payment for Production: Althea shall invoice Client for and Client shall pay Althea the amounts respectively set forth in the
related PWA, in accordance with the invoicing and payment schedule set forth therein, for all Production and other Services performed under this Agreement. Client shall pay all invoices within [***] of receipt. Past due amounts shall bear interest
at the lesser of (a) the maximum rate permitted by law, and (b) [***]% per [***] on the outstanding balance compounded monthly, subject to the right of Client to dispute in good faith any such amount for so long as Client promptly and
diligently pursues resolution of such disputes. 
 Althea’s wire instructions are as follows: 

 

			
	Beneficiary:	 	Althea Technologies, Inc.
		 	11040 Roselle Street
		 	San Diego CA 92121
		
	Bank:	 	[***]
	SWIFT #:	 	[***]
	Transit #:	 	[***]
	Account #:	 	[***]

 For at least [***] after completion of the relevant Service(s) under this Agreement (or for such longer period of time as may
be required by applicable Legal Requirements), Althea shall maintain 
 accurate books, records, documents, and other evidence of costs, expenses and
allowances which are either related to costs and expenses incurred by Althea which are reimbursable by Client under this Agreement, or Althea’s related mitigation efforts. Client, or at Client’s expense Client’s independent public
accountants of recognized national standing selected by Client [***], shall have a right to examine and audit such records upon at least [***] prior written notice at mutually agreed times and places. 

Althea shall notify Client promptly and within at least [***] if Althea becomes aware that Client is entitled to a refund or reimbursement of amounts paid by
Client under this Agreement, and amounts due and owing by Althea to Client under this Agreement shall, at Client’s option, either be paid by Althea to Client within [***] of Althea’s receipt of a written request for payment, or be applied
against amounts to become payable by Client to Althea under subsequent invoices issued by Althea under this Agreement. 
 2.9
Default in Payment Obligations: In addition to all other remedies available to Althea in the event of a Client default, if Client fails to timely pay amounts properly due and payable under this Agreement (subject to the foregoing right of
Client to dispute in good faith any amounts charged hereunder, which, for purposes of this Agreement, shall not be considered past due, so long as Client promptly and diligently pursues resolution of such disputes), [***] Althea may take other
appropriate 

  

					
	ALTHEA & ALDER CONFIDENTIAL	  	7	  	FINAL

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 
measures to assure prompt and full payment, including [***], placing the account on a letter of credit basis, requiring full or partial payment in advance, [***], and/or taking other reasonable
means as Althea may determine. [***] 
 2.10 Returns; Complaints: Client Product returned by third parties will be administered and
managed by Client. Client shall have responsibility for reporting any complaints relating to the Product to the FDA and any other Regulatory Authorities, including without limitation complaints relating to the Production of the Product and adverse
drug experience reports. Client shall maintain complaint files in accordance with cGMP. Althea shall provide Client with a copy of any complaints received by Althea with respect to the Product in accordance with the Quality Agreement and applicable
SOPs. Client shall have responsibility for [***] promptly providing Althea with a copy of any responses to complaints [***]. Althea shall promptly respond to requests from Client for information in Althea’s possession that is reasonably
necessary for Client to respond to complaints [***]. Additional procedures for complaint reporting and responses are set forth in the Quality Agreement. 
  

	3.	TERM AND TERMINATION. 

 3.1 Term: This Agreement shall commence on the Effective
Date and will continue until the later of (a) [***], and (b) the date on which the Production services, as described in the last outstanding PWA, have been completed, unless sooner terminated pursuant to Section 3.2 herein (the
“Term”). Each PWA shall commence on the effective date set forth therein and, unless earlier terminated, shall expire when the Production, as described in such PWA, has been completed. The termination of this
Agreement shall automatically and without further action by either party terminate all PWAs that are outstanding on the date of termination. The termination of any individual PWA shall not affect the other PWAs or this Agreement. 

3.2 Termination: Any PWA, and this Agreement, may be terminated at any time upon the occurrence of any of the following events:

 (a) Termination for Breach: Either party may terminate any PWA, and may terminate this Agreement in its entirety, upon the
material breach (which shall include any breach of payment terms) of this Agreement, the Quality Agreement [***] by the other party if such breach is not cured by the breaching party within [***] (or such additional time reasonably necessary to cure
such breach, not to exceed an additional [***], provided the breaching party has commenced a cure within the [***] period and is diligently pursuing completion of such cure and such cure is reasonably anticipated within [***] of the
non-breaching party’s notice of breach) after receipt by the breaching party of written notice of such breach. 
 (b) Termination
for Financial Matters: This Agreement may be terminated immediately by either party by giving the other party written notice thereof in the event such other party makes a general assignment for the benefit of its creditors, or proceedings of a
case are commenced in any court of competent jurisdiction by or against such party seeking (a) such party’s reorganization, liquidation, dissolution, arrangement or winding up, or the composition or readjustment of its debts, (b) the
appointment of a receiver or trustee for or over such party’s property, or (c) similar relief in respect of such party under any law relating to bankruptcy, insolvency, reorganization, winding up or composition or adjustment of debt, and
such proceedings shall continue undismissed, or an order with respect to the foregoing shall be entered and continue unstayed, for a period of more than [***]. 

(c) Termination by Client: Client shall have the right to terminate any PWA, and shall have the right to terminate this Agreement, with
or without cause, with at least [***] written notice to Althea. 

  

					
	ALTHEA & ALDER CONFIDENTIAL	  	8	  	FINAL

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 3.3 Payment on Termination-Cancellation Fees: In the event of cancellation by Client
of the Production activities set forth in the relevant PWA, or in the event of termination of this Agreement, (collectively, a “Cancellation”, except for termination in the event of a material breach by Althea pursuant to
Section 3.2(a) or a force majeure event affecting Althea pursuant to Article 7), Client shall pay or reimburse Althea, to the extent not previously paid, for: 

(a) all Althea Supplied Components with respect to the Client Product ordered prior to Cancellation, that are not cancelable without
cost to Althea (at the acquisition cost), or in the alternative cancellation costs, if cancelable, 
 (b) all work-in-process with
respect to the Client Product performed by Althea (at a reasonable rate, based on the Purchase Price for completed Production and completed Client Product), and 

(c) all completed Production and completed Client Product (at the Purchase Price). 

If a cancellation fee is applicable under the terms of the related PWA or if the parties otherwise have agreed that a cancellation fee is applicable (in
either case, a “Cancellation Fee”), then Client shall in addition to the payments and reimbursements above pay Althea the applicable Cancellation Fee. If no Cancellation Fee is specified in the related PWA or has been otherwise agreed, and
Client gives notice of a Cancellation less than [***] prior to the scheduled initiation of Production, then Client shall pay a reasonable Cancellation Fee in an amount which shall be [***]. Any upfront or advance payments made by Client, if not
applied to Services already rendered, will be credited against the amounts payable under this Section 3.3. 
 3.4 Survival:
Termination or expiration of this Agreement through any means or for any reason, shall be without prejudice to any accrued obligation or the rights and remedies of either party with respect to any antecedent breach of any of the provisions of
this Agreement, subject to Section 12.1. The provisions of Articles 3, 6, 9, 10, 11, 12, 13, 14, and 15 hereof shall survive expiration or termination of this Agreement, as will any other provision which by its nature should have validity
beyond the expiration or termination of this Agreement. 
 3.5 Consequences of Expiration or Termination: After receiving or
providing notice of cancellation or termination of this Agreement or a PWA, Althea shall promptly act to mitigate and cancel, to the extent commercially reasonable, all obligations that would incur expense related to the Agreement or the cancelled
or terminated PWA, as applicable; and Althea shall not, without Client’s prior approval, perform any additional Production, incur expenses (other than those reasonably required by the cancellation or termination (e.g. orderly termination of
Production activities, waste and Components disposition, etc.)), or enter into any other obligations related to this Agreement or the cancelled or terminated PWA, as applicable. Upon cancellation, termination or expiration of this Agreement or a
PWA, Althea shall make no further use of and, unless otherwise directed by Client, shall in accordance with Client’s instructions, either ship to Client or its designated consignee, store [(***)], or destroy, all Client Supplied Components, all
Althea Supplied Components, all work-in process and any other materials and supplies paid for by Client, all Client Product, and all other Client Information and Materials which are pertinent to this Agreement or such PWA, as applicable, subject, in
each case, to Client’s payment obligations with respect thereto. Notwithstanding the foregoing, Althea may, in accordance with the terms of the applicable PWA(s) or the Quality Agreement or as required by applicable Legal Requirements, retain
information, records and materials, provided that retained information, records and materials may be used for documentation purposes only and provided further that, notwithstanding anything to the contrary
in this Agreement, for so long as Althea retains such information, records and materials and until it destroys or delivers to Client or its designated consignee the retained information, records and materials, the obligations of nonuse and
confidentiality set forth in the Agreement shall not expire pursuant to Section 9.6 and shall continue to apply to the retained information, records and materials. 

  

					
	ALTHEA & ALDER CONFIDENTIAL	  	9	  	FINAL

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 3.6 Technology Transfer. The Parties intend that the Process shall be fully portable
by Client. At any time and from time to time during the term of this Agreement, and within [***] following the expiration or termination of this Agreement, Althea shall, at the request of Client, transfer to Client (or its designee) the Process for
the Client Product and all manufacturing technology and know-how related thereto (“Technology Transfer”). A Technology Transfer shall include at least the following activities: (a) Althea shall provide all pertinent information
necessary or useful to manufacture the Product and to support regulatory filings for the Product, including without limitation [***], and other process and manufacturing data and documentation; (b) Althea shall provide training sessions and
reasonable assistance and cooperation [***] in order to enable Client or its designee to manufacture the Product; (c) Althea shall provide Client or its designee with access to Althea employees with expertise in manufacturing to answer
questions related to such Technology Transfer; and (d) Althea will use reasonable efforts to assist Client or its designee to secure terms for applicable components and raw materials from Althea’s suppliers of such components and raw
materials. A Technology Transfer shall be charged on a [***]. For each Technology Transfer, the parties shall [***]. 
  

	4.	CERTIFICATES OF ANALYSIS AND MANUFACTURING COMPLIANCE. 

 4.1 Certificates of Analysis:
At Client’s cost and expense, Althea shall test, or cause to be tested by third parties, in accordance with the Specifications, each Batch of Client Product Produced pursuant to this Agreement before delivery to Client. Althea shall deliver
a Certificate of Analysis for each Batch, which shall set forth the items tested, Specifications, and test results. Althea shall also indicate on the final page of the Released Executed Batch Record that all batch Production and control records have
been reviewed and approved by the appropriate quality control unit. Althea shall send, or cause to be sent, such certificates to Client prior to the shipment of Client Product (unless Client Product is shipped under quarantine). If Client is
responsible for final release testing, or if Client otherwise deems it appropriate, Client shall test, or cause to be tested, for final release, each Batch of Client Product to test for conformance to the Specifications. [***] 

4.2 Manufacturing Compliance: Althea shall advise Client immediately if an authorized agent of any Regulatory Authority schedules or
visits (or gives notice that it intends to schedule or visit) Althea’s manufacturing facility and makes an inquiry regarding Althea’s Production of Client Product for Client. Client shall be entitled to be present during any such
inspection or visit, and shall be further entitled to attend any end of visit wrap-up meeting with such regulatory agent, if feasible. [***] Althea shall promptly provide Client with a copy of any report or findings of such Regulatory Authority
relevant to Production or Client Product and of Althea’s intended response prior thereto to enable the parties to confer on such matter. 

4.3 Reserve Samples: Each party shall perform its respective obligations with respect to retention and reserve sample in accordance
with the applicable provisions of the Quality Agreement. 
 4.4 [Reserved] 

4.5 Distribution Records: Althea shall maintain for the time periods required by applicable Legal Requirements all of its manufacturing
and analytical records, shipment and distribution records and validation data relating to Client Product supplied hereunder, all of which shall contain all of the appropriate information as specified in cGMP. 

4.6 Audits: Client shall have the right, at mutually agreed times and during normal business hours, [***] to inspect, [***] (per
project or per campaign, as applicable) for not more than [***], for its 

  

					
	ALTHEA & ALDER CONFIDENTIAL	  	10	  	FINAL

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 
[***] cGMP audit, and at such additional times as are reasonable to ascertain corrections following a finding of deficiency by Client during [***] audit or by a Regulatory Agency, Althea Batch
records and the portions of the Facility used for Production of Client Product. If the parties agree to audits (other than and not including for-cause audits) more than [***] or for more than [***], [***]. All audited data (other than and not
including Client’s Confidential Information) will be treated as Confidential Information of Althea, and Client shall not be permitted to remove or copy such audit data without Althea’s prior consent provided, however, that the
preceding limitation shall not be construed to limit Client’s access to, or use of, such audit data for purposes of conducting its audit or receipt of executed Master Batch Records for regulatory or other purposes. 

4.7 Regulatory Compliance: Althea is responsible for compliance with all Legal Requirements which are applicable to the operations in
which it is engaged and its obligations under this Agreement and the Quality Agreement, including, for example, the laws and regulations which apply generally to manufacture of drugs. Client shall be responsible for compliance with all Legal 

 Requirements which are applicable to all other aspects of the manufacture of Client Product, and to the use, and sale of Client Product, which
responsibility shall include, without limitation, all contact with the FDA regarding the foregoing. 
 4.8 Person in the Plant: As
further described in the Quality Agreement, and subject to and in accordance with Althea’s SOPs and other terms jointly agreed regarding access (time and place) to Althea’s Facility, Client shall have the right to designate [***]
representatives of Client to be present at any one time in the Althea Facility during normal business hours and at any other times while active Production is occurring to observe the Production and observe Althea’s performance of Services under
this Agreement 
  

	5.	ACCEPTANCE OF CLIENT PRODUCT. 

 5.1 Non-Conforming Client Product: Within [***]
from the date of completion of testing and Althea’s release of Batch of Client Product, Althea shall promptly forward to Client, or Client’s designee, copies of the Released Executed Batch Record and samples of such Batch. Within [***]
after receipt by Client of such samples together with the documentation, Client shall perform any testing it deems appropriate and review the documentation in order to determine, subject to Client’s rights below, whether Client Product is
Conforming. 
 (a) If (i) such Batch of Client Product is Conforming, or (ii) Client does not notify Althea within
the applicable [***] time period that such Batch of Client Product is non-Conforming, then Client shall be deemed to have accepted the Client Product and waived its right to revoke acceptance; provided however that Client shall have the right
to revoke acceptance for any Batch which is non-Conforming under all of the following conditions: [***]. 
 Alternatively, rather than initially issuing a
notice of rejection, Client may given written notice to Althea within the time period specified in this Section 5.1(a) of a Client decision to investigate whether a potentially non-Conforming Batch should be rejected, which investigation shall,
unless otherwise agreed by Client and Althea, be completed within the time period set forth in this Section 5.1(a). 
 (b) If
Client believes any Batch of Client Product is non-Conforming, it shall notify Althea [***], including a detailed explanation of the non-conformity, and shall [***]. Upon receipt of such notice, Althea will investigate such alleged non-conformity,
and (i) if Althea agrees such Client Product is non-Conforming, deliver to Client a corrective action plan within [***] after receipt of Client’s [***] notice of non-conformity, or such additional time as is reasonably required if such
investigation or 

  

					
	ALTHEA & ALDER CONFIDENTIAL	  	11	  	FINAL

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 
plan requires data from sources other than Client or Althea, or (ii) if Althea disagrees with Client’s determination that the Batch of Client Product is non-Conforming, Althea shall so
notify Client [***] within the [***] period [***]. 
 (c) If the parties dispute whether Client Product is Conforming, samples of the
Batch of Client Product will be [***] for resolution, whose determination of Conformity, and the cause thereof if non-Conforming, [***]. The fees of the laboratory or consultant shall be paid by [***], with each party 

initially paying directly to the laboratory or consultant one-half of the fees[***]. 

(d) For clarity, the parties agree that deviations and investigations may or may not result in non-Conforming Client Product, and that
the occurrence of a deviation or investigation does not, in and of itself, deem Client Product to be non-Conforming. The provisions set forth in the Quality Agreement shall control whether manufacturing deviations and investigations result in
non-Conforming Client Product. 
 5.2 Exclusive Remedies for Non Conforming Product: In the event Althea agrees, [***], that the
Batch of Client Product is non-Conforming and the non-Conformity was caused by Althea’s negligence or more culpable act or omission or Althea’s breach of this Agreement, the Quality Agreement or the related PWA, and Client rejects the
Batch, (or, in the event of a [***], Client revokes acceptance of the Batch in accordance with Section 5.1(a)), then Althea, at Client’s option, shall either: 

(i) subject to Client’s supply of the replacement Client Supplied Components ([***]), and [***], replace such non-Conforming Bulk Drug,
Drug Product or Finished Product, as the case may be, with conforming Bulk Drug, Drug Product or Finished Product, as applicable, within the following timeframes: (a) for Production of replacement Bulk Drug, within [***] from receipt of
replacement Client Supplied Components from Client, and (b) for Production of replacement Drug Product or Finished Product where Althea Produced the Bulk Drug or Drug Product for the non-Conforming Batch, within [***] from Client’s
election of remedies under this Section 5.2, or 
 (ii) upon demand, refund the Purchase Price of the non-Conforming Client Product
[***]. 
 In addition, in either (i) or (ii), Althea shall, if applicable, reimburse Client upon demand at Client’s cost for the value of the
related resins or other Components which were supplied or paid for by Client, to the extent the life span of such resins or other Components has been shortened or such resins or other Components have been rendered unusable (contamination, etc.).

 If the parties agree [***] that Client Product is non-Conforming due in whole or in part to (a) non-conforming Client Supplied Components for which
Client has testing and release responsibilities, (b) other matters which are the responsibility of Client, or (c) non-conforming Client Supplied Components for which Althea has testing and release responsibilities, where the non-conformity
was a latent defect that was not discoverable, at time of delivery, by reasonable testing of the Components and review of related documentation, then: (1) if the non-Conformity is due in whole to such matters, then Client will not be entitled
to the foregoing remedies, and (2) if the non-Conformity is due in part to such matters, then Althea’s financial responsibility under this Section 5.2 will be proportionately reduced based on the extent to which such matters
contributed to the non-Conformity. In addition, if Client elects the remedy under Section 5.2(i) above, the final invoice to be issued at completion of Production of said non-Conforming Batch of Client Product will not be issued and the amounts
due thereunder will not be payable until the date at which replacement Client Product is released and determined to be Conforming by Althea and Client. 

  

					
	ALTHEA & ALDER CONFIDENTIAL	  	12	  	FINAL

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

	6.	CLIENT PRODUCT RECALLS. 

 In the event Client shall be required to recall any Client Product because such
Client Product may violate local, state or federal laws or regulations, or the laws or regulations of any applicable U.S. or foreign government or agency, or is non-Conforming, or in the event that Client elects to institute a voluntary recall,
withdrawal, field alert or similar action (collectively a “Recall”), Client shall be responsible for coordinating such Recall. Client promptly shall notify Althea if any Client Product is the subject of a Recall and provide Althea with a
copy of all documents relating to such Recall. Althea shall reasonably cooperate with Client in connection with any Recall, at Client’s expense (subject to Althea’s payment obligations below in this Article 6). Client shall be responsible
for all of the costs and expenses of such Recall, except in the event and to the extent such Recall is caused by [***], in which case Althea shall on demand reimburse Client for the actual documented cost of such Recall [***]. For clarity, such
reimbursement is in addition to any remedies Client may have under Section 5.2 for such [***]. 
  

	7.	FORCE MAJEURE; FAILURE TO SUPPLY. 

 7.1 Force Majeure Events: Failure of either
party to perform under this Agreement (except the obligation to make payments) shall not be a breach of this Agreement if such failure is caused by any event beyond the reasonable control of and without the fault or negligence of the party affected
thereby, including acts of God, acts of terrorism, fire, explosion, flood, drought, war, riot, sabotage, embargo, strikes or other labor trouble, or compliance with any order or regulation of any government entity, [***],
provided that written notice of such event is promptly given by the affected party to the other party. In the case of a force majeure event, Althea shall use commercially reasonable efforts to arrange for the Production of
Client Product through subcontracting or other means as appropriate, subject to Client’s prior written consent, to provide Conforming Client Product meeting Specifications and produced in substantial compliance with the Althea SOPs. The
responsibility for any differential in the cost for such Production will be [***]. However, if Althea is unable to provide a solution for the Production of Client Product within [***] of such event, Client may terminate this Agreement as specified
in Section 3.2(a) of this Agreement. 
 7.2 Failure to Supply: If Althea fails to supply all or any material part of
Client Product ordered by Client, Client may require Althea to supply the undelivered Client Product or a lesser quantity at a future date agreed upon by Althea and Client. The provisions of this Section 7.2 shall be without prejudice to
Client’s other rights and remedies at law and in equity, including under Section 3.2 and remedies provided for thereunder. 
  

	8.	CHANGES IN PRODUCTION. 

 8.1 Changes to Master Batch Records and Specifications:
Althea agrees to inform Client within [***] of the result of any regulatory development or changes to Client Product-specific Althea SOPs that materially affect the Production of Client Product. Althea shall notify Client of and require written
approval from Client for changes to Master Batch Records and Client Product Specifications prior to the Production of subsequent Batches of Client Product. 

8.2 Product-Specific Changes: If facility, equipment, process or system changes are required of Althea as a result of requirements set
forth by the FDA or any other Regulatory Authority, and such regulatory changes apply only to the Production and supply of one or more Client Products, then  

Client and Althea will review such requirements and agree in writing to such regulatory changes, [***]. 

8.3 General Changes: If such regulatory changes apply generally to the Client Product as well as to other products produced by Althea
for itself or for third parties, then [***]. If the regulatory 

  

					
	ALTHEA & ALDER CONFIDENTIAL	  	13	  	FINAL

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 
change is of such a nature that it applies to contract manufacturers providing services of the type provided generally by Althea and Althea may not offer certain services to Client under this
Agreement as a result, [***]. 
 8.4 Changes: Any change to any Specifications, any aspect of Production, or any vendor or supplier
of Components, shall be in accordance with the Quality Agreement. 
  

	9.	CONFIDENTIALITY. 

 9.1 Confidentiality. 

9.1.1 For purposes of this Agreement “Confidential Information” means (a) all information and data
disclosed or provided by or on behalf of one party to the other party in connection with this Agreement, whether in oral, written, graphic or electronic form, (b) with respect to Client, all information and data developed in or as a result of
the performance of this Agreement which describes or is related to Client Product, Alder Technology, Client’s Intellectual Property, Alder Technology Inventions or other Inventions or Intellectual Property of Client, whether in oral, written,
graphic or electronic form, and (c) with respect to Althea, all information and data developed in or as a result of the performance of this Agreement which describes or is related to Inventions or Intellectual Property of Althea, whether in
oral, written, graphic or electronic form. Without limiting the generality of the foregoing, all Inventions and Intellectual Property of a party shall be deemed the “Confidential Information” of such party. Client’s Confidential
Information includes, without limitation, (i) the Alder Technology, (ii) the Production Process, and (iii) the technical and other information contained in or relating to the documents and records describing or otherwise related to
the Production Process (including, without limitation, the MBR and the other Batch records), the cell line(s) for Client Product, the master and working cell bank(s) for Client Product, and/or Client Product. For clarity, the Confidential
Information described in Section 9.1.1(b) above shall be deemed the “Confidential Information” of Client, and, with respect thereto, Althea shall be deemed to be the Receiving Party; and the Confidential Information described in
Section 9.1.1(c) above shall be deemed the “Confidential Information” of Althea, and, with respect thereto, Client shall be deemed to be the Receiving Party. 

9.1.2 Each party (the “Receiving Party”) agrees, with respect to the Confidential Information of the other
party (the “Disclosing Party”): (a) to use such Confidential Information only for the purposes set forth in this Agreement; (b) to receive, maintain and hold the Confidential Information in strict confidence and to
use the same methods and degree of care (but at least reasonable care) to prevent disclosure of such Confidential Information as it uses to prevent disclosure of its own proprietary and Confidential Information and to protect against its
dissemination to unauthorized parties; (c) not to disclose, or authorize or permit the disclosure of any Confidential Information to any third party without the prior written consent of the Disclosing Party; and (d) except as needed to
fulfill its obligations hereunder, to return any Confidential Information to the Disclosing Party at the request of the Disclosing Party and to retain no copies or reproductions thereof, except that the Receiving Party may retain a single archival
copy of the Confidential Information for the sole purpose of determining the scope of obligations incurred under this Agreement. 

  

					
	ALTHEA & ALDER CONFIDENTIAL	  	14	  	FINAL

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 9.2 Limitations. The Receiving Party shall not be obligated to treat information as
Confidential Information of the Disclosing Party if the Receiving Party can show by competent written evidence that such information: (a) was already known to the Receiving Party without any obligations of confidentiality prior to receipt from
the Disclosing Party; (b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party; (c) became generally available to the public or otherwise part of the public
domain after its disclosure, through no fault of the Receiving Party; (d) was disclosed to the Receiving Party, other than under an obligation of confidentiality, by a third party who had no obligation not to disclose such information to
others; or (e) was independently discovered or developed by the Receiving Party without the use of or reference to the Disclosing Party’s Confidential Information. 

9.3 Authorized Disclosure. Notwithstanding Section 9.1, the Receiving Party may disclose Confidential Information, without
violating its obligations under Article 9, to the extent the disclosure is required by a valid order of a court or other governmental body having jurisdiction; provided, however, that the Receiving Party gives reasonable prior
written notice to the Disclosing Party of such required disclosure and makes a reasonable effort to assist the Disclosing Party in obtaining, a protective order preventing or limiting the disclosure and/or requiring that the Confidential Information
so disclosed be used only for the purposes for which the law or regulation requires, or for which the order was issued, and thereafter discloses only the minimum Confidential Information required to be disclosed in order to comply, whether or not a
protective order or other similar order is obtained by the Disclosing Party. 
 The Receiving Party will limit access to the Confidential Information
of the Disclosing Party to only those of the Receiving Party’s employees or authorized representatives having a need to know in connection with such party’s performance of its obligations under this Agreement and who are bound by
obligations of confidentiality and non-use consistent with and at least as stringent as those set forth herein. 
 Notwithstanding the foregoing,
Althea shall be permitted to disclose Client Product information to third party developmental and analytical service providers who are permitted subcontractors hereunder and who have a need to know such information in connection with performance of
its obligations hereunder, provided such providers shall be subject to and bound by obligations of confidentiality and non-use consistent with and at least as stringent as those set forth herein. 

No provision of this Agreement shall be construed so as to preclude the use or disclosure of Confidential Information as may be reasonably necessary for
Client to secure any regulatory or governmental approvals or licenses with respect to Client Product, or of either party to obtain patents related to its Inventions and Intellectual Property, or to limit either party’s ownership of, or ability
to use its Intellectual Property. 
 9.4 Injunctive Relief. The parties expressly acknowledge and agree that any breach or threatened
breach of this Article 9 may cause immediate and irreparable harm to the Disclosing Party which may not be adequately compensated by damages. Each party therefore agrees that in the event of such breach or threatened breach and in addition to any
remedies available at law, the Disclosing Party shall have the right to seek equitable and injunctive relief, without bond, in connection with such a breach or threatened breach. 

9.5 Public Announcements. The parties acknowledge that it is their intention not to issue a press release or make any other public
announcement of the execution of this Agreement. All publicity, press releases and other announcements relating to this Agreement shall be reviewed in advance by, and subject to the approval of, both parties (which approval shall not be unreasonably
withheld); provided, however, that either party may (a) disclose the terms of this Agreement insofar as required to comply with applicable securities laws, provided that in the case of such disclosures the party proposing
to make such 

  

					
	ALTHEA & ALDER CONFIDENTIAL	  	15	  	FINAL

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 
disclosure notifies the other party reasonably in advance of such disclosure and cooperates to minimize the scope and content of such disclosure, and (b) disclose the terms of this Agreement
to such party’s investors, professional advisors or potential investors, acquirers, or merger candidates, on a need to know basis, who are bound by obligations of confidentiality and non-use consistent with those set forth herein. Each party
agrees that it shall cooperate fully and in a timely manner with the other with respect to any disclosures to the Securities and Exchange Commission and any other governmental or regulatory agencies, including requests for confidential treatment of
Confidential Information of either party included in any such disclosure. 
 9.6 Duration of Confidentiality: Except as otherwise
provided in Section 3.5 of this Agreement, all obligations of confidentiality and non-use imposed upon the parties under this Agreement shall expire [***] after the expiration or earlier termination of this Agreement; provided, however,
that Confidential Information which constitutes the trade secrets of a party shall be kept confidential indefinitely and shall remain subject to the confidentiality and non-use provisions of this Article 9 indefinitely, subject to the limitations
set forth in Sections 9.2 and 9.3. 
  

	10.	INVENTIONS. 

 10.1 Existing Intellectual Property; Alder Technology Inventions:

 (a) Except as the parties may otherwise expressly agree in writing, each party shall continue to own its existing patents,
trademarks, copyrights, trade secrets and other Intellectual Property, without conferring any interests therein on the other party. 

(b) Without limiting the generality of the preceding sentence, Client shall retain all right, title and interest arising under the
United States Patent Act, the United States Trademark Act, the United States Copyright Act and all other applicable laws, rules and regulations relating to ownership of the tangible and/or intangible attributes of any and all Alder Technology,
Client Product, the cell lines for Client Product, the cell banks for Client Product, the Labeling and trademarks associated therewith, and/or the Process, and including all Intellectual Property rights therein, regardless of authorship,
inventorship or the identity of the party of creation or development (collectively, and including Alder Technology Inventions described in Section 10.1(c) below, “Client’s Intellectual Property”). Neither Althea nor
any third party shall acquire any right, title or interest in Client’s Intellectual Property by virtue of this Agreement or otherwise. 

(c) As between the parties, Client shall own all rights in and title to the Alder Technology and the biological materials described as
the cell lines for Client Product, the cell banks for Client Product, and/or the Client Product, and any and all improved or enhanced versions of the foregoing and any derivatives or variants of the foregoing that are created by either party in the
course of or resulting from this Agreement and/or the Quality Agreement. All Inventions that relate to or comprise any Alder Technology, any cell line for Client Product, any cell bank for Client Product, and/or the Client Product (collectively,
“Alder Technology Inventions”) shall be assigned to, solely owned by, and subject to use and exploitation by Client, without a duty to account to Althea. Althea [***]. Althea hereby assigns and shall assign the Alder
Technology Inventions to Client. Client shall be entitled to file patent applications worldwide with respect to such Inventions. Althea shall promptly disclose Alder Technology Inventions to Client. Althea shall make and maintain accurate written
records of Alder Technology Inventions, and provide the same to Client upon request. Althea shall and shall cause its employees and agents to, [***], provide reasonable assistance to Client to permit Client to obtain and enforce the full benefits,
enjoyment, rights and title throughout the world in the Alder Technology Inventions, and Client shall [***] for such assistance or for Client’s ownership, use or exploitation of the Client Inventions. 

  

					
	ALTHEA & ALDER CONFIDENTIAL	  	16	  	FINAL

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 (d) To the extent any Invention(s) are conceived, reduced to practice, or created
solely or jointly by Althea, its personnel or contractors and meet all of the following requirements, then to that extent such Invention(s) shall be retained by Althea (subject to sole or joint ownership as provided by applicable law): (a) the
Invention is not an Alder Technology Invention (as set forth above, all Alder Technology Inventions shall be solely owned by Client), (b) the Invention was not derived from Client’s Confidential Information, and (c) the Invention does
not contain claims covering any Alder Technology, the cell lines for Client Product, the cell banks for Client Product and/or the Client Product 

10.2 Individually [***] Inventions: Subject to and except as otherwise provided under Section 10.1, and except as the parties may
otherwise agree in writing, all Inventions which are conceived, reduced to practice, or created by a party in the course of performing its obligations under or resulting from this Agreement shall be solely owned and subject to use and exploitation
by the inventing party without a duty to account to the other party, provided that Althea shall promptly disclose such Inventions to Client and, upon request, Althea shall grant Client a [***] license [(***)] to practice any
intellectual property created by Althea in the course of performing its obligations under this Agreement, to the extent necessary for Client to make, have made, use, sell, offer and import Client Product. 

10.3 [***] Inventions: Subject to and except as otherwise provided under Section 10.1, all Inventions which are conceived, reduced
to practice, or created jointly by the parties and/or their respective employees or agents (i.e., employees or agents who would be or are properly named as co-inventors under the laws of the United States on any patent application claiming such
Inventions) in the course of the performance of or resulting from this Agreement shall be owned [***], and [***] shall have full rights to exploit such Inventions for its own commercial purposes without any obligation or duty of accounting to [***].
[***] The decision to file for patent coverage on [***] Inventions shall be [***], and [***] shall select a [***] patent counsel to file and prosecute patent applications based on such joint Inventions. 

10.4 Disclaimer: Except as otherwise expressly provided herein, nothing contained in this Agreement shall be construed or interpreted,
either expressly or by implication, estoppel or otherwise, as: (i) a grant, transfer or other conveyance by either party to the other of any right, title, license or other interest of any kind in any of its Inventions or other Intellectual
Property, (ii) creating an obligation on the part of either party to make any such grant, transfer or other conveyance or (iii) requiring either party to participate with the other party in any cooperative development program or project of
any kind or to continue with any such program or project. 
 10.5 Rights in Inventions: The party owning any Invention shall
have the world wide right to control the drafting, filing, prosecution and maintenance of patents covering the Inventions relating to such Invention, including decisions about the countries in which to file patent applications. Patent costs
associated with the patent activities described in this Article shall be home by the sole owner. Each party will cooperate with the other party in the filing and prosecution of patent applications. Such cooperation will include, but not be limited
to, furnishing supporting data and affidavits for the prosecution of patent applications and completing and signing forms needed for the prosecution, assignment and maintenance of patent applications. 

  

					
	ALTHEA & ALDER CONFIDENTIAL	  	17	  	FINAL

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 10.6 Confidentiality of Inventions: Inventions shall be deemed to be the Confidential
Information of the party(ies) owning such Inventions. Any disclosure of an Invention by one party to the other under the provisions of this Article 10 shall be treated as the Confidential Information of the owner(s) of the Invention under this
Agreement. It shall be the responsibility of the party preparing a patent application to obtain the written permission of the other party to use or disclose the other party’s Confidential Information in the patent application before the
application is filed and for other disclosures made during the prosecution of the patent application. 
 10.7 No Employee or
Agent: The parties agree that, for purposes of this Article 10, neither party shall be considered an “employee or agent” of the other party. 
  

	11.	REPRESENTATIONS AND WARRANTIES. 

 11.1 Mutual Representations: Each party hereby
represents and warrants to the other party that (a) such party is duly organized, validly existing, and in good standing under the laws of the place of its establishment or incorporation, (b) such party has taken all action necessary to
authorize it to enter into this Agreement and perform its obligations under this Agreement, (c) subject to the execution of this Agreement by such party, this Agreement has been duly executed and constitutes the legal, valid and binding
obligation of such party, (d) neither the execution of this Agreement nor the performance of such party’s obligations hereunder will conflict with, result in a breach of, or constitute a default under any provision of the organizational
documents of such party, or of any law, rule, regulation, authorization or approval of any government entity, or of any agreement to which it is a party or by which it is bound, and (e) it is not currently a party to, and during the term of
this Agreement will not enter into, any agreements that are inconsistent with its obligations under this Agreement. 
 11.2 Althea
Warranty: 
 11.2.1 [Reserved] 

11.2.2 Althea represents and warrants as follows: 

(a) Client Product shall be and has been Produced in accordance with the Specifications (including in- process
Specifications) and cGMP, subject to Section 5.1(d); 
 (b) the Production activities performed by Althea shall be and
have been performed in compliance with the requirements of all applicable material Legal Requirements; [***]; and provided, further, that this Section 11.2.2(b) shall not imply and Althea expressly disclaims any warranty from Althea
regarding the activities performed by Alder (or performed by third parties on behalf of Alder), including Alder’s or such third party’s designs, formulations, Specifications, clinical or preclinical testing, use, marketing, packaging or
labeling of Client Product or any claims made by Alder or such third party regarding safety or efficacy of Client Product; and 
 (c)
when delivered to Client, Client Product shall and does conform to the Specifications. 
 provided, however, that, with respect to Client Product
resulting from development or engineering runs, [***] and, with respect to Client Product resulting from development or engineering runs, Althea represents and warrants [***] that that Client Product shall be and has been Produced in accordance with
agreed initial target process Specifications and those portions of cGMP which are expressly made applicable in the PWA to the development or engineering runs. 

  

					
	ALTHEA & ALDER CONFIDENTIAL	  	18	  	FINAL

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 11.2.3 Except for any liens or encumbrances, if any, of Althea, securing Client’s
payment obligations under this Agreement, Client Product shall be and has been transferred free and clear of any liens or encumbrances of any kind arising through Althea or its Affiliates or their respective agents or subcontractors. 

11.2.4 Althea represents and warrants that it has obtained (or will obtain prior to Producing Client Product) and will
maintain, and will remain in compliance with during the Term, all permits, licenses and other authorizations (the “Permits”) which are required under federal, state and local Legal Requirements applicable to the
Production services; provided, however, for clarity, the parties acknowledge that Althea shall have no obligation to obtain Permits relating to the sale (except any that may be required for the sale of Client Product by Althea to Client under
this Agreement), marketing, distribution or use of Client Product, or with respect to the Labeling of Client Product (except for Permits required for Labeling services to be performed by Althea under a PWA). Althea shall maintain its Facility in
accordance with cGMP and other applicable Legal Requirements. 
 11.2.5 Althea represents and warrants that [***], and
covenants that it will [***] Althea shall promptly notify Client if it becomes aware of any [***]. 
 11.3 Client Warranties:
Client represents and warrants that (a) it has the right to give Althea any information provided by Client hereunder, and that Althea has the right to use such information for the Production of Client Product, and (b) Client has no
knowledge of any (i) patents or other intellectual rights that would be infringed or misappropriated by Althea’s Production of Client Product under and in accordance with this Agreement, or (ii) proprietary rights of third parties
which would be violated by Althea’s Production of Client Product under and in accordance with this Agreement. 
 11.4
Disclaimer of Warranties: Except as expressly set forth in this Agreement, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY NON-INFRINGEMENT, MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE. 
  

	12.	LIMITATION OF LIABILITY AND WAIVER OF SUBROGATION. 

 12.1 Limitation of Liability:

 (a) In addition to and without limitation of any other remedies available at law and in equity, but in all cases subject to
Section 12.1(b) below, Client may require that any deficient, defective or nonconforming Services be reperformed, corrected or replaced, at Althea’s expense. 

(b) Notwithstanding Section 12.1(a) above, Client’s sole and exclusive remedies for delivery of non-Conforming Client Product
(and, for avoidance of doubt, for delivery of Bulk Drug Substance, Drug Product, and/or Finished Product that is not Conforming) is limited to those remedies set forth in Article 5 and 6 and its termination rights set forth in Article 3. 

(c) UNDER NO CIRCUMSTANCES SHALL EITHER PARTY BE LIABLE FOR ANY CONSEQUENTIAL DAMAGES, INCLUDING LOSS OF USE OR PROFITS, OR ANY
INDIRECT, INCIDENTAL, SPECIAL, OR PUNITIVE DAMAGES WHICH ARISE OUT OF OR ARE RELATED TO THIS AGREEMENT (COLLECTIVELY, “CONSEQUENTIAL DAMAGES”), INCLUDING BUT NOT LIMITED TO CONSEQUENTIAL DAMAGES WHICH CONSIST OF 

(EXCEPT AS SET FORTH IN ARTICLE 5) THE COST OF COVER, OR, (EXCEPT AS SET FORTH IN ARTICLE 6), THE COST OF A RECALL, AND ALSO INCLUDING BUT NOT LIMITED TO
CONSEQUENTIAL DAMAGES WHICH ARISE OUT OF OR ARE RELATED TO THE 

  

					
	ALTHEA & ALDER CONFIDENTIAL	  	19	  	FINAL

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 
PRODUCTION AND DELIVERY OR NON-DELIVERY OF CLIENT PRODUCT UNDER THIS AGREEMENT, WHETHER SUCH CLAIMS ARE FOUNDED IN TORT OR CONTRACT. THE FOREGOING LIMITATIONS OF LIABILITY SHALL NOT APPLY TO
OBLIGATIONS AND CLAIMS ARISING UNDER ARTICLE 13 (INDEMNIFICATION), OR IN THE EVENT OF BREACH OF A PARTY’S OBLIGATIONS OF CONFIDENTIALITY OR NON-USE, OR A PARTY’S MISUSE OR MISAPPROPRIATION OF A PARTY’S INTELLECTUAL PROPERTY RIGHTS, OR
IN THE EVENT OF A PARTY’S GROSS NEGLIGENCE, WILLFUL MISCONDUCT, OR CRIMINAL CONDUCT. 
 12.2 Waiver of Property Claims: All
Althea Supplied Components and equipment used by Althea in the Production of Client Product (collectively, “Althea Property”) shall at all times remain the property of Althea. [***]. Althea hereby waives any and
all rights of recovery against Client and its Affiliates, and against any of their respective directors, officers, employees, agents or representatives, for [***]. [***]. 

12.3 Waiver of Development Claims: If Client retains Althea under a PWA to provide consulting services for the development of Client
Product, and Althea makes recommendations to Client regarding the development of Client Product, Althea represents and warrants [***]. 
  

	13.	INDEMNIFICATION. 

 13.1 Client Indemnification: Client hereby agrees to defend,
indemnify and hold harmless Althea and its Affiliates and their respective officers, directors, employees, contractors, consultants and agents (each, an “Althea Indemnitee”) from and against [***] (a
“Claim”) against an Althea Indemnitee, including [***] (“Losses”), arising or resulting from (a) Client’s storage, promotion, labeling, marketing, distribution,
use or sale of Client Product (including without limitation any Client Product or any other product of Client for which Althea provided development recommendations, as contemplated under Section 12.3 above), (b) Client’s negligence or
willful misconduct, (c) Client’s material breach of this Agreement, any PWA, or the Quality Agreement, or (d) any claim that the use, sale, marketing or distribution of Client Product by Client, or the Production of Client Product by
Althea in accordance with the Specifications, violates the patent, trademark, copyright or other proprietary rights of any third party, except to the extent any such Claims or Loss(es) arise or result from the negligence or willful misconduct of any
of the Althea Indemnitees or Althea’s breach of this Agreement, any PWA, or the Quality Agreement,. 
 13.2 Althea
Indemnification: Subject to and except to the extent of any indemnification from Client pursuant to Section 13.1 above, Althea hereby agrees to defend, indemnify and hold harmless Client and its Affiliates and their respective directors,
officers, employees, subcontractors and agents  
 (each, a “Client Indemnitee”) from and against any and all
Claims against a Client Indemnitee and Losses with respect thereto, to the extent arising or resulting from the negligence or willful misconduct of any of the Althea Indemnitees, or from the Althea’s material breach of this Agreement, any PWA,
or the Quality Agreement. 
 13.3 Indemnitee Obligations: A party (the “Indemnitee”) that
intends to make a claim for indemnification under this Article 13 shall promptly notify the other party (the “Indemnitor”) in writing of any action, claim or other matter in respect of which such Indemnitee or any of its
Affiliates, or any of their respective directors, officers, employees, subcontractors, or agents, intends to claim such indemnification; provided, however, that failure to provide such notice within a reasonable period of time shall not
relieve the Indemnitor of any of its obligations hereunder except to the extent the Indemnitor is prejudiced by such failure. The Indemnitee shall permit, and shall cause its Affiliates, and their 

  

					
	ALTHEA & ALDER CONFIDENTIAL	  	20	  	FINAL

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 
respective directors, officers, employees, subcontractors and agents to permit, the Indemnitor, at its discretion, to settle any such action, claim or other matter, and the indemnified party
agrees to the complete control of such defense or settlement by the Indemnitor. Notwithstanding the foregoing, the Indemnitor shall not enter into any settlement that would adversely affect the Indemnitee’s rights hereunder, or impose any
obligations on the indemnified party in addition to those set forth herein in order for it to exercise such rights, without indemnified party’s prior written consent, which shall not be unreasonably withheld or delayed. [***] The Indemnitee,
its Affiliates, and their respective directors, officers, employees, subcontractors and agents shall fully cooperate with the Indemnitor and its legal representatives in the investigation and defense of any action, claim or other matter covered by
the indemnification obligations of this Article 13. The indemnified party shall have the right, but not the obligation, to be represented in such defense by counsel of its own selection and at its own expense. 

 

	14.	INSURANCE. 

 14.1 Client Insurance: Client shall procure and maintain, from the
Effective Date through the date that is [***] after the expiration date of all Client Product Produced under this Agreement, Commercial General Liability Insurance, including without limitation, [***] (the “Client
Insurance”). The Client Insurance shall cover amounts not less than $[***] combined single limit and shall be with an insurance carrier reasonably acceptable to Althea. Althea shall be named as an additional insured on the
Client Insurance and Client promptly shall deliver a certificate of Client Insurance and endorsement of additional insured to Althea evidencing such coverage. If Client fails to furnish such certificates or endorsements, or if at any time during the
Term Althea is notified of the cancellation or lapse of the Client Insurance, and Client fails to rectify the same within [***] after notice from Althea, Althea, at its option, may terminate this Agreement. Any deductible and/or self insurance
retention shall be the sole responsibility of Client. 
 14.2 Althea Insurance: Althea shall procure and maintain, from the
Effective Date through the date that is [***] after the expiration date of all Client Product Produced under this Agreement, Commercial General Liability Insurance, including without limitation, [***] (the “Althea
Insurance”). The Althea Insurance shall cover amounts not less than $[***] combined single limit. Client shall be named as an additional insured on the Althea Insurance. 

14.3 Waiver of Subrogation: Each party hereby waives any and all rights of recovery against the other party and its Affiliates, and
against any of their respective directors, officers, employees, agents or representatives, for any loss or damage to the extent the loss or damage is covered by insurance (whether or not such insurance is described in this Agreement). 

 

	15.	GENERAL PROVISIONS. 

 15.1 Notices: Any notice to be given under this Agreement
must be in writing and delivered either in person, by any method of mail (postage prepaid) requiring return receipt, or by overnight courier (charges prepaid), or facsimile confirmed thereafter by any of the foregoing, to the party to be notified at
its address given below, or at any address such party has previously designated by prior written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the actual delivery thereof at the address designated in accordance
with this paragraph. 
  

			
	If to Client:	  	Alder BioPharmaceuticals, Inc.
		  	11804 North Creek Parkway South
		  	Bothell WA 98011 USA
		  	Attention: Mark Litton
		  	Telephone: (425) 205-2920
		  	Facsimile: (425) 205-2901

  

					
	ALTHEA & ALDER CONFIDENTIAL	  	21	  	FINAL

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

			
	If to Althea:	  	Althea Technologies, Inc.
		  	11040 Roselle Street
		  	San Diego, CA 92121
		  	Attn: Chief Financial Officer
		  	Telephone: (858) 882-0123
		  	Facsimile: (858) 882-0133

 For specific inquiries, the following Althea responsible parties may be contacted directly: 

 

			
	Project Manager	 	Melissa Rosness or her designee
	Quality Control and Quality Assurance	 	EJ Brandreth or his designee
	Materials Manager	 	James Andrade

 For specific inquiries, the following Client responsible parties may be contacted directly: 

 

			
	Project Manager:	 	Dauphine Barone or her designee
	Quality Control Manager:	 	Annette Vahratian or her designee
	Materials Manager:	 	Dauphine Barone or her designee
	Quality Assurance Manager:	 	Annette Vahratian or her designee

 15.2 Entire Agreement; Amendment: The parties hereto acknowledge that this Agreement, including any
Appendices hereto and any PWAs incorporated into this Agreement from time to time, together with the Quality Agreement, sets forth the entire agreement and understanding of the parties with respect to the subject matter hereof and supersedes all
prior written or oral agreements or understandings with respect to the subject matter hereof. For clarity, the parties agree that the Drug Product Development and Clinical Supply Agreement between the parties dated effective as of [***], and the
terms thereof continue in force and are not affected by this Agreement. No modification of any of the terms of this Agreement, or any amendments or Appendices, shall be deemed to be valid unless in writing and signed by an authorized agent or
representative of both parties hereto. No course of dealing or usage of trade shall be used to modify the terms and conditions herein. 

15.3 Waiver: None of the provisions of this Agreement shall be considered waived by any party hereto unless such waiver is agreed to,
in writing, by an authorized agent of the waiving party. The failure of a party to insist upon strict conformance to any of the terms and conditions hereof, or failure or 

delay to exercise any rights provided herein or by law shall not be deemed a waiver of any rights of any party hereto. 

15.4 Assignment: This Agreement may [***]. No assignment shall relieve either party of the performance of any accrued obligation that
such party may then have under this Agreement. This Agreement shall inure to the benefit of and be binding upon each party signatory hereto, its successors and permitted assigns, subsidiaries and Affiliates. 

15.5 Taxes: Client shall pay all national, state, municipal or other sales, use, excise, import, property, value added, or other
similar taxes, assessments or tariffs assessed upon or levied against the sale of Client Product to Client pursuant to this Agreement or the sale or distribution of Client Product by Client (or at Client’s sole expense, defend against the
imposition of such taxes and expenses). Althea shall notify Client of any such taxes that any governmental authority is seeking to collect from Althea, and Client may assume the defense thereof in Althea’s name, if necessary, and Althea agrees
to fully cooperate in such defense to the extent of the capacity of Althea, at Client’s expense. Althea shall pay all other national, state, municipal or other taxes on the fees payable and expenses reimbursable under this Agreement, including
on the income resulting from the sale by Althea of the Client Product to Client under this Agreement, including but not limited to, gross income, adjusted gross income, supplemental net income, gross receipts, excess profit taxes, or other similar
taxes. 

  

					
	ALTHEA & ALDER CONFIDENTIAL	  	22	  	FINAL

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 15.6 Independent Contractor: Althea is and shall act as an independent contractor for
Client in providing the services required hereunder and is not and shall not be considered an agent of, partner of, or joint venturer with, Client. Unless otherwise provided herein to the contrary, Althea shall furnish all expertise, labor,
supervision, machining and equipment necessary for performance hereunder and shall obtain and maintain all building and other permits and licenses required by public authorities or Regulatory Authorities. 

15.7 Governing Law; Limitations: This Agreement is being delivered and executed in the State of [***]. In any action brought regarding
the validity, construction and enforcement of this Agreement, it shall be governed in all respects by the laws of the State of [***], without regard to the principles of conflicts of laws. 

15.8 Dispute Resolution: 

15.8.1 The parties recognize that a bona fide dispute as to certain matters may from time to time arise during the Term of this
Agreement which relates to a party’s rights and/or obligations hereunder. In such a dispute occurs, a party may, by notice to the other party or parties, as applicable, have such dispute referred to their respective personnel set forth below,
or their successors or designees, for attempted resolution by good faith negotiations within [***] after such notice is received. Such personnel are as follows: 
  

			
	For Althea:	  	Chief Financial Officer
	Contact Information:	  	Althea Technologies, Inc.
		  	11040 Roselle Street
		  	San Diego CA 92121
		  	Telephone: (858) 882-0200
		
	For Client:	  	Mark Litton
	Contact Information:	  	Alder BioPharmaceuticals, Inc.
		  	11804 North Creek Parkway South
		  	Bothell WA 98011 USA
		  	Attention: Mark Litton
		  	Telephone: (425) 205-2920
		  	Facsimile: (425) 205-2901

 If such personnel are not able to resolve such dispute within such [***] period, or such other period of time as the parties
may mutually agree in writing, each party shall have the right to pursue any and all remedies available at law or in equity, subject to Section 15.8.2. 

15.8.2 Subject to Section 15.8.3, [***] either party may [***] any such dispute be resolved by [***] arbitration administered by
the American Arbitration Association, in accordance with its commercial arbitration rules, [***]. The number of arbitrators shall be three, and the arbitrators shall be appointed in accordance with such rules. The place of arbitration will be [***].
Each party shall bear its own attorneys’ fees and associated costs and expenses, subject to Section 15.9. Any award rendered by the arbitrators shall be in writing, [***]. Judgment on an award rendered may be entered in any court of
competent jurisdiction, or application may be made to any such court for a judicial acceptance of the award and an order of enforcement, as appropriate. [***]. 

  

					
	ALTHEA & ALDER CONFIDENTIAL	  	23	  	FINAL

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 15.8.3 Notwithstanding anything in this Section 15.8 seemingly to the contrary,
either party may seek injunctive relief from a court of competent jurisdiction to prevent or limit damage to that party’s Intellectual Property. 

15.9 Attorney’s Fees: [***]. 

15.10 Severability: In the event that any one or more of the provisions contained herein, or the application thereof in
any circumstances, is held invalid, illegal or unenforceable in any respect for any reason, the parties shall negotiate in good faith with a view to the substitution therefor of a suitable and equitable provision in order to carry out, so far as may
be valid and enforceable, the intent and purpose of such invalid provision; provided, however, that the validity, legality and enforceability of any such provision in every other respect and of the remaining provisions contained herein shall
not be in any way impaired thereby, it being intended that all of the rights and privileges of the parties hereto shall be enforceable to the fullest extent permitted by law. 

15.11 Preference: Unless otherwise specifically provided to the contrary in any exhibit or schedule to this Agreement, in the event of
a conflict between the main body of this Agreement and the 
 exhibits and schedules hereto, the terms of the main body of this Agreement shall
control. And, unless otherwise specifically provided to the contrary in the Quality Agreement, in the event of a conflict between this Agreement and the Quality Agreement, the terms of this Agreement shall control. 

15.12 Headings; Construction: The headings in this Agreement, each PWA, and the Quality Agreement, and any attachments thereto, are for
convenience of reference only and shall not affect its interpretation. Unless the context clearly indicates otherwise, singular references in this Agreement, the PWAs, the Quality Agreement, and any attachments thereto, shall include the plural and
vice versa, and the terms “include” and “including” mean including without limitation. 
 15.13 Counterparts;
Facsimile Signatures: This Agreement may be executed in counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same agreement. This Agreement shall be effective upon full
execution, and a signature transmitted via facsimile or other electronic means shall be deemed to be and shall be as effective as an original signature. 

IN WITNESS WHEREOF, the parties hereto have each caused this Product Development and Clinical Supply Agreement to be executed by their
duly-authorized representatives as of the Effective Date above written. 
  

									
	ALDER BIOPHARMACEUTICALS, INC.	 		 	ALTHEA TECHNOLOGIES, INC.
					
	By:	 	 /s/ Mark J. Litton
	 		 	By:	 	 /s/ William Kachioff

					
	Name:	 	 Mark J. Litton
	 		 	Name:	 	 William Kachioff

					
	Title:	 	 CBO
	 		 	Title:	 	 Vice President, Finance & CFO

					
		 		 		 		 	 2011.05.26    15:02:15-07’00

  

					
	ALTHEA & ALDER CONFIDENTIAL	  	24	  	FINAL

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 Appendix A 

PWA TEMPLATE 
 [to be
agreed by the parties] 

  

					
	ALTHEA & ALDER CONFIDENTIAL	  	25	  	FINAL

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}]]